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Preclinical studies of vascular disruptive and anti-angiogenic agents, combined with 
radiation, have demonstrated the potential for enhanced anti-tumour activity. 
However, the optimal strategy and scheduling for combining these treatments with 
radiotherapy remains uncertain. In this thesis, combretastatin-A4-phosphate (CA4P) 
given concurrently with fractionated radiotherapy has been studied using preclinical 
models, in addition to assessing the impacts of adding the nitric oxide synthase 
inhibitor, N(omega)-nitro-L-arginine (L-NNA), or the anti-EGFR monoclonal antibody, 
cetuximab, to this combination. As part of an ongoing phase Ib clinical trial, the 
combination of CA4P and radiotherapy was investigated in patients with non-small 
cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), 
where concurrent cetuximab was also given.  
 
Functional imaging techniques, such as dynamic contrast enhanced (DCE)-CT and 
positron emission tomography (PET), provide non-invasive biomarkers, which can 
be harnessed to aid diagnosis, determine response to treatment and also offer 
prognostic information. The use of volumetric DCE-CT parameters as biomarkers of 
tumour hypoxia and angiogenesis in NSCLC has been explored here, with 
significant negative correlations demonstrated between DCE-CT parameters and 
immunohistochemical staining of intra-tumoural hypoxia. This illustrates the potential 
ability of volumetric DCE-CT to quantify whole tumour hypoxia in NSCLC. 
 
The translational research described in this thesis, has established that the vascular 
disruptive effects of CA4P can be safely used in combination with fractionated 
radiotherapy in the clinical setting, producing demonstrable tumour vascular effects. 
However, despite promising preclinical tumour growth delay effects, the addition of 
cetuximab produced dose-limiting cardiotoxicity. In patients receiving CA4P and 
 4
radiotherapy, DCE-CT and circulatory biomarkers, including cytokines (VEGF, 
VEGFR-1, G-CSF and SDF-1), were utilised to assess treatment-induced changes 
in tumour vascularity and vasculogenesis. The findings in this thesis provide further 
information to guide future studies combining vascular targeted therapies and 
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(#&#$&';.#! +461P-'! D\'1! #&! '.98! I@@?H9! :+#! $1%*#N2#%$#! 1,! +461P-$! *&3#**! -*! &+#!
263#/2.'&-1%! 1,! '%/-1/#%-$! ,'$&13*8! &+#! #,,#$&! 1,! 7+-$+! -*! &+#! $3#'&-1%! 1,! '! %#7!
)'*$2.'3!*266.4!DQ<..'.2%-*!#&!'.98!>CCCS8!Q=252023'8!h2!#&!'.98!I@@>SH9!T%!.'&#3!*&'/#*!
+461P-'!*&31%/.4!-%(2$#*!%#1'%/-1/#%#*-*8!#*6#$-'..4!)-'!+461P-'[-%(2$-;.#!,'$&13!>!
'.6+'! DWT=[>ĮH! 6'&+7'49! <$&-)'&-1%! 1,! &+-*! 6'&+7'4! ;4! +461P-'! -%(2$#*! &+#!
631(2$&-1%!1,!631'%/-1/#%-$!,'$&13*8!-%$.2(-%/!BYJ=!DQ=13*4&+#!#&!'.98>CCFS8!Q"')-!#&!
'.98! I@@@SH9! ]#6&-(#! ;.1$5'/#! 1,! WT=[>Į! (#/3'('&-1%! +'*! *-0-.'3! #,,#$&*! 631(2$-%/!




:J=[D8! TM[E! '%(! WJ=! DW'33-*8! I@@IH9! M17! #P&3'$#..2.'3! 6W! '.*1! 263#/2.'&#*!
#P63#**-1%!1,!631'%/-1/#%-$!,'$&13*8!-%$.2(-%/!BYJ=!'%(!TM[E!Dh2!#&!'.9!I@@IH9!
!
:+#!+1*&-.#!+461P-$! '%(!'$-(1&-$! &20123!0-$31#%)-31%0#%&! 6.'4*!'! 5#4! 31.#! -%! &+#!
;#+')-123! 1,! &20123*8! ;2&! '.*1! -%! &+#-3! 3#*61%*-)#%#**! &1! &3#'&0#%&9! T&! *#.#$&*!




*-/%-,-$'%&.4! 3#(2$#! 3'(-1*#%*-&-)-&48! -&! '.*1! 3#(2$#*! *#%*-&-)-&4! &1! $#3&'-%!
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$+#01&+#3'6#2&-$!'/#%&*!-%$.2(-%/!$'3;16.'&-%!'%(!;.#104$-%!D`1$+!#&!'.98!I@@GH9!<!
3#(2$&-1%! -%! #,,#$&! 1,! $+#01&+#3'64! -*! '.*1! (#*$3-;#(!7-&+! '$-(-$! #P&3'$#..2.'3! 6W8!
631(2$-%/!'%!'$$202.'&-1%!1,!$#..*!-%!J>!6+'*#!'%(!'.*1!3#(2$-%/!$#..2.'3!26&'5#!1,!
7#'5!;'*#!'/#%&*! -%$.2(-%/!(1P132;-$-%!'%(!0-&1P'%&31%#! DB251)-$! '%(!:'%%1$58!
>CCKH9!!
 
1.3  Therapeutic targeting of tumour vasculature!
>9G9>!! B'*$2.'3!(-*326&-1%!
B'*$2.'3! (-*326&-)#! '/#%&*! DBX<*H! #P#3&! &+#-3! #,,#$&! ;4! &+#! &'3/#&-%/! 1,! #P-*&-%/!
&20123! )'*$2.'&23#8! #P6.1-&-%/! &+#! (-,,#3#%$#*! ;#&7##%! &20123! '%(! %130'.! ;.11(!
)#**#.*9! :+#*#! &3#'&0#%&*! +')#! ;##%! (#)#.16#(! 7-&+! &+#! '-0! 1,! 631(2$-%/! 3'6-(!
&20123!$#..!-*$+'#0-'8!3#*2.&-%/!-%!&20123!$#..!(#'&+9!:+#!#P'$&!0#$+'%-*0*!1,!+17!
&+#*#! '/#%&*! #P#3&! &+#-3! '%&-[&20123! '$&-1%! '3#! $106.#P! '%(! 3#0'-%! 2%(#3!
-%)#*&-/'&-1%9! :+#! )'*$2.'3! (-*326&-)#! '/#%&*! $233#%&.4! -%! (#)#.160#%&! $'%! ;#!
;31'(.4! (-)-(#(! -%&1! &71! $.'**#*j! *0'..! 01.#$2.#! '%(! .-/'%(! (-3#$&#(9! :+#! *0'..!






>CGK! +')#! #P6.13#(! -&*! #,,#$&*! 1%! &20123! )'*$2.'&23#! '%(! (#01%*&3'&#(8! -%! ;1&+!
'%-0'.! '%(! +20'%! &20123*8! &+#! ';-.-&4! &1! -%(2$#! +'#0133+'/#! '%(! #P&#%*-)#!
%#$31*-*! DQL14.'%(! '%(! L14.'%(8! >CGKS8! QR##(! #&! '.98! >CV@S9! R-/%-,-$'%&! )'*$2.'3!
#,,#$&*!+')#!'.*1!;##%!1;*#3)#(!7-&+!&+#!$4&1&1P-$!'%(!61&#%&!&2;2.-%[;-%(-%/!)-%$'!
'.5'.1-(*8! )-%$3-*&-%#! '%(! )-%;.'*&-%#! DW-..! #&! '.98! >CCGH9! ! :+#! )'*$2.'3! #,,#$&*!
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1;*#3)#(!7-&+!;1&+!$1.$+-$-%#*!'%(!&+#!)-%$'!'.5'.1-(*!1$$23!1%.4!'&!(1*#*!$.1*#!&1!




A#7#3! &2;2.-%[;-%(-%/! )'*$2.'3! (-*326&-%/! '/#%&*! 1,,#3-%/! '! .'3/#3! &+#3'6#2&-$!
7-%(178!-%$.2(-%/!&+#!$10;3#&'*&'&-%*8!+')#!*-%$#!;##%!(#)#.16#(9!:+#*#!'$&!'&!&+#!
$1.$+-$-%#[;-%(-%/! *-&#! 1,! E[*2;2%-&! 1,! #%(1&+#.-'.! $#..! &2;2.-%! DM-%! #&! '.98! >CEEH9!
:46-$'..4! &+#4!631(2$#!'! 3'6-(! 3#(2$&-1%! -%! &20123!6#3,2*-1%!7-&+!0'P-0'.! &20123!
)'*$2.'3! *+2&(17%! *##%! 1%#! &1! *-P! +123*! 61*&! '(0-%-*&3'&-1%8! 7-&+! *2;*&'%&-'.!
3#$1)#34! 1,! &20123! ;.11(! ,.17! ;4! IV! +123*! D]3-*#! #&! '.98! I@@IH9! <$&-)'&-1%! 1,! &+#!
"+1k"+1[5-%'*#!6'&+7'4! $'2*#*!0-$31&2;2.#!(#61.40#3-*'&-1%!'%(! 3#01(#..-%/!1,!
&+#! '$&-%! $4&1*5#.#&1%! D`'%&+12! '%(! :1c#38! I@@IH9! <$&-)'&-1%! 1,! *&3#**['$&-)'&#(!
631&#-%!I!DR<]`IH!'.*1!1$$23*9!:+#*#!#,,#$&*!631(2$#!&+3##[(-0#%*-1%'.!$+'%/#*!-%!
&+#!*+'6#!1,!#%(1&+#.-'.!$#..*b!013#!631%12%$#(!-%!%#7.4!,130#(!1%#*!'*!&+#4!.'$5!
'! 7#..[(#)#.16#(! '$&-%! $4&1*5#.#&1%! '%(! 6#3-$4&-$! -%,-.&3'&-1%9! T%$3#'*#(! )'*$2.'3!
3#*-*&'%$#!'%(!'.*1!-%$3#'*#(!)'*$2.'3!6#30#';-.-&4!1$$23*8!'*!&+#3#!-*!(-*326&-1%!1,!
&+#! 01.#$2.'3! #%/'/#0#%&! 1,! &+#! #%(1&+#.-'.! $#..[*6#$-,-$! _2%$&-1%'.! 01.#$2.#*8!
-%$.2(-%/! )'*$2.'3! #%(1&+#.-'.[$'(+#3-%! DBY[$'(+#3-%H! DB-%$#%&! #&! '.98! I@@?H9!
\10;3#&'*&'&-%[-%(2$#(!)'*$2.'3!$1..'6*#8!1;*#3)#(!7-&+!\<V]!'%(!<\KK@@8!0'4!
;#! 3#.'&#(! &1! '3&#3-1.'3! )'*1$1%*&3-$&-1%! 3#(2$-%/! -%&3')'*$2.'3! 63#**23#8! 7+-$+!
3#*2.&*! -%! '%! -%$3#'*#! -%! &+#! (-,,#3#%&-'.! ;#&7##%! -%&#3*&-&-'.! ,.2-(! 63#**23#! '%(! &+#!
-%&3')'*$2.'3! $'6-..'34! 63#**23#! DQ:1c#3! #&! '.98! I@@>S8! QW13-! '%(! R'-&18! I@@GSH9!
\1%&3'34!&1!63#)-12*!$1%_#$&23#!1%!&+#!0#$+'%-*0!.#'(-%/!&1!&+-*!)'*$2.'3!$1..'6*#8!










3#*2.&! -%! -%-&-'&-1%! 1,! &+#! $1'/2.'&-1%! $'*$'(#! 631(2$-%/! &+310;2*! '%(! 3#(2$-%/!
&20123! ;.11(! ,.17! D:1c#3! #&! '.98! I@@?H9! T%$3#'*#(! %#2&316+-.! 3#$32-&0#%&! -*! '.*1!
(#*$3-;#(!'%(! &+-*8! -%!'((-&-1%! &1!263#/2.'&-1%!1,!#%(1&+#.-'.! $#..! *23,'$#!'(+#*-1%!
01.#$2.#*8!0'4!$1%&3-;2&#!&1!;1&+!&+#!)'*$2.'3!'%(!$4&1&1P-$!#,,#$&*!1,!&+#*#!*0'..!
01.#$2.#! BX<*! DL3115*! #&! '.98! I@@GH9! l%(#3! '#31;-$! $1%(-&-1%*! \<V]! -%$3#'*#*!
WT=[>! #P63#**-1%! 3#*2.&-%/! -%! '%! -%$3#'*#(!631(2$&-1%! 1,!BYJ=[<8! +17#)#3! 2%(#3!
+461P-$! $1%(-&-1%*! '! 3#(2$&-1%! -%! &+#! '$$202.'&-1%! 1,! WT=[>! +'*! ;##%! 1;*#3)#(!
DX'$+*!#&!'.98!I@@GH9!:+#!'%/-1/#%-$!3#*61%*#!&1!\<V]!+'*!;##%!*&2(-#(!2*-%/!'%!
-%! )-)1! %1%! *0'..! $#..! .2%/! $'3$-%10'! DAR\M\H! P#%1/3',&! 01(#.8! 7-&+! -%$3#'*#(!
#P63#**-1%! 1,! ;1&+! BYJ=! '%(! ;=J=! (#01%*&3'&#(! DL1#+.#! #&! '.98! I@@>H9! <*! '!
$1%*#N2#%$#!1,!\<V][-%(2$#(!)'*$2.'3!(-*326&-1%8!&+#3#!-*!'%!'$2&#!01;-.-*'&-1%!1,!
$-3$2.'&-%/! #%(1&+#.-'.! 631/#%-&13! $#..*! ,310! &+#! ;1%#! 0'33178! 7-&+! &+#*#! $#..*!
0-/3'&-%/!&1!'%(!.1$'.-*-%/!-%!&+#!3#*-(2'.!)-';.#!3-0!1,!&20123!DR+'5#(!#&!'.98!I@@FH9!
!
\<V]! D,1*;3#&';2.-%! Qm4;3#*&'&SH! -*! '! *4%&+#&-$8! 7'&#3! *1.2;.#8! 6+1*6+134.'&#(!
631(32/!1,!&+#!%'&23'.!631(2$&!$10;3#&'*&'&-%!<V!D\<VH9!Z3-/-%'..4!-*1.'&#(!,310!&+#!
;'35! 1,! &+#!\'6#!;2*+7-..178!Combretum caffrum, \<V! -*! '! &2;2.-%[;-%(-%/! '/#%&!









+123*! DX'35! #&! '.98! >CCKH9! YP&#%*-)#! +'#0133+'/-$! %#$31*-*! '%(! &20123! $#..! .1**!
7#3#! 1;*#3)#(8! ;2&! 7-&+! %1! (#01%*&3';.#! #,,#$&! 1%! &20123! /317&+9! :+-*! #,,#$&! -*!
'&&3-;2&#(! &1! &+#! '$&-)#.4! 631.-,#3'&-%/! 3-0! 1,! &20123! $#..*! 3#0'-%-%/8! &+12/+&! &1!
3#$#-)#! -&*!;.11(! *266.4! ,310!*23312%(-%/!%130'.! &-**2#! D\+'6.-%! #&!'.! >CCCH9!:+#!
)'*$2.'3!'3$+-&#$&23#!1,! &+#! &20123!6#3-6+#34!'%(! &+#!63#$-6-&12*! 3-*#! -%! -%&#3*&-&-'.!
,.2-(! 63#**23#! ,310! &+#! &20123! 6#3-6+#34! &1! &+#! $#%&3#! '3#! '.*1! &+12/+&! &1! ;#!
$1%&3-;2&-%/!,'$&13*!&1!&+#!6#3*-*&#%$#!1,!&+-*!)-';.#!3-0!D:1c#3!#&!'.98!I@@?H9!
!
:+#! $.-%-$'.! 6+'30'$15-%#&-$! ('&'! ,310! &+3##!]+'*#! T! $.-%-$'.! &3-'.*! +'*! %17! ;##%!
3#613&#(9!:+#!6.'*0'!<l\!'%(!\0'P!1,!\<V]!'%(!-&*!'$&-)#!0#&';1.-&#!\<V!+')#!
;##%!(#01%*&3'&#(!&1!-%$3#'*#!.-%#'3.4!7-&+!(1*#!DR&#)#%*1%!#&!'.98!I@@GH9!!\<V]!-*!
3'6-(.4! $1%)#3&#(! &1! \<V8! 7+-$+! -*! &+#%! #P&#%*-)#.4! $1%)#3&#(! &1! &+#! /.2$231%-(#!
D\<VJH9! Y*&-0'&#*! 1,! 0#'%! 6.'*0'! +'.,[.-,#! ,13! \<V]8! \<V8! '%(! \<VJ! 7#3#!
'6631P-0'&#.4!@9V>8!G9E@8!'%(!V9VE!+123*8! 3#*6#$&-)#.49!L#&7##%!?En!'%(!FKn!1,!
&+#!\<V]!(1*#!-*!#P$3#&#(!'*!\<VJ!-%!&+#!23-%#!7-&+-%!IV!+123*!1,!'(0-%-*&3'&-1%9!
<&! &+#! ?V0/k0I! (1*#! .#)#.8! /-)#%! '*! '! *-%/.#! (1*#! #)#34! I>! ('4*8! &+#! 0#'%!
Di*&'%('3(! (#)-'&-1%H! 0'P-020! $1%$#%&3'&-1%! D\0'PH! )'.2#*! 1,! \<V]! '%(! \<V!
7#3#!V@!DiVH!'%(!I9F!Di!@9EH!oa!3#*6#$&-)#.48!D%pFH9!!
!
:+#! (1*#! .-0-&-%/! &1P-$-&-#*! DXM:*H! 7-&+! *-%/.#! (1*#! \<V]! #)#34! I>! ('4*! 7#3#!
$'3(-'$! -*$+'#0-'!'%(!(4*6%1#'8! *##%!'&! &+#! C@0/k0I!(1*#! .#)#.! DX17.'&-! #&! '.98!
I@@IH9!!Z%#!6'&-#%&8!&3#'&#(!'&!&+#!F@0/k0I!(1*#!.#)#.8!+'(!631)#%!$.-%-$'.!#)-(#%$#!
1,!041$'3(-'.!-*$+'#0-'!7-&+!Y\J!$+'%/#*!'%(!3'-*#(!&3161%-%!.#)#.*8!7-&+!'%1&+#3!
6'&-#%&!'&! &+-*!(1*#! .#)#.!(#)#.16-%/!*-/%-,-$'%&!q:$!631.1%/'&-1%! Dq:$!!?@@!0*H9!
:+#! XM:*8! ,13! \<V]! '(0-%-*&#3#(! '*! ,-)#! ('-.4! (1*#*! #)#34! I>! ('4*8! -%$.2(#(!
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&20123! 6'-%8! 3#)#3*-;.#! *#%*13-01&13! %#2316'&+48! *4%$16#! '%(! (4*6%1#'! '&! &+#!
K?0/k0I!(1*#!.#)#.!DR&#)#%*1%!#&!'.98!I@@GH9!! T%!&+#!*&2(4!.115-%/!'&! &+3##!7##5.4!
(1*#*! 1,! \<V]! #)#34! IE! ('4*! &+#! XM:*! 7#3#! 3#)#3*-;.#! '&'P-'! '&! >>V0/k0I8!
)'*1)'/'.! *4%$16#! '%(! 01&13! %#2316'&+4! '&! EE0/k0I! '%(! ,'&'.! -*$+'#0-'! -%!
63#)-12*.4!-33'(-'&#(!;17#.!'&!?I0/k0I!D"2*&-%!#&!'.98!I@@GH9!!Z&+#3!&+'%!&+#!;17#.!
-*$+'#0-'8!&+#*#!#)#%&*!'..!3#*1.)#(!-%!.#**!&+'%!>I!+123*9!!Z&+#3!J3'(#!I!13!+-/+#3!









:+#*#! $+'%/#*! -%! ;.11(! 63#**23#! '%(! $'3(-'$! 12&62&! '3#! &+12/+&! &1! ;#! (2#! &1!
\<V][-%(2$#(!)'*$2.'3!*011&+!02*$.#!$1%&3'$&-1%!631(2$-%/! -%$3#'*#(!6#3-6+#3'.!
)'*$2.'3! 3#*-*&'%$#8!'%! -%(#6#%(#%&!#,,#$&! &+'&! -*!%1&! 3#N2-3#(! ,13! &+#!(-*326&-1%!1,!
&20123!)'*$2.'&23#!D<%(#3*1%!#&!'.98!I@@G'H9!]3#$.-%-$'.!*&2(-#*!+')#!*+17%!&+'&8!-%!
&+#! 63#*#%$#! 1,! 63##P-*&-%/! +46#3&#%*-1%8! '! /3#'&#3! ;.11(! 63#**23#! 3-*#! -*! *##%!
,1..17-%/!\<V]8!'**1$-'&#(!7-&+!-%$3#'*#(!$'3(-'$!*&3'-%!(#01%*&3';.#!;4!'!3-*#!-%!
$'3(-'$!#%c40#*!D`#!q!#&!'.98!I@@KH9!:+#*#!;.11(!63#**23#!'%(!$'3(-'$!#,,#$&*!$'%!




q:$! -%&#3)'.8! 7-&+! '%! -%$3#'*#! 1,! rI@! 0*#$! $1001%.4! *##%! '&! (1*#*! 3'%/-%/!
;#&7##%!GK!'%(!C@0/k0I9!T%$3#'*#*!/3#'&#3!&+'%!F@!0*#$!+')#!;##%!1;*#3)#(!-%!'!
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*0'..!%20;#3!1,!6'&-#%&*8!'.&+12/+!%1!q:$! -%&#3)'.!1,!?@@!0*#$!7'*!*##%! -%! &+#!
&+3##!0'-%!]+'*#! T! *&2(-#*9! :+#!6'&-#%&*! -%! &+#*#! *&2(-#*!7#3#! +17#)#3! $'3#,2..4!




1%#! 6'&-#%&!7-&+! '%'6.'*&-$! &+431-(! $'3$-%10'!'%(! /3#'&#3! &+'%! >I!01%&+! (-*#'*#!
*&';-.-*'&-1%!*##%!-%!&71!1&+#3!6'&-#%&*9!U-&+!&+#!,-)#!('-.4!(1*#*!#)#34!&+3##!7##5*8!
1%#! 6'&-#%&! 7-&+! *'3$10'! +'(! '! 6'3&-'.! 3#*61%*#! '%(! ,123&##%! 1&+#3*! +'(! *&';.#!
(-*#'*#9!Z%#!6'3&-'.!3#*61%*#8!-%!'!6'&-#%&!7-&+!0#&'*&'&-$!'(3#%1$13&-$'.!$'3$-%10'8!
7'*!'.*1!*##%!7-&+!&+#!*$+#(2.-%/!1,!&+3##!7##5.4!(1*#*!#)#34!,123!7##5*9!U-&+!&+#!






\<V]! +'*! ;##%! *+17%! &1! #%+'%$#! 13! '$&! *4%#3/-*&-$'..4! 7-&+! *#)#3'.! $4&1&1P-$!
$+#01&+#3'64!'/#%&*9!T%!)-)1!*&2(-#*!+')#!*+17%!;#%#,-&!7-&+!&+#!'((-&-1%!1,!\<V]!
&1! $-*6.'&-%! -%! 0'00'34! $'3$-%10'8! 1)'3-'%! $'3$-%10'! '%(! *'3$10'! 01(#.*b! ?[
,.213123'$-.! -%! '! $1.1%-$! $'3$-%10'! 01(#.b! (1P132;-$-%! -%! '! 0#(2..'34! &+431-(!
$'3$-%10'! 01(#.b! $4$.16+1*6+'0-(#! -%! ;3#'*&! $'3$-%10'! '%(! *'3$10'! 01(#.*b!











63-13! &1! $'3;16.'&-%! <l\! ?! '%(k! 13! 6'$.-&'P#.! (#01%*&3'&-%/! '! 7#..! &1.#3'&#(!
$10;-%'&-1%!7-&+!0-%-0'.!04#.1*2663#**-1%9!\233#%&!]+'*#!TTkTTT!&3-'.*!'3#!1%/1-%/8!
-%$.2(-%/! '! ]+'*#! TT! &3-'.! $10;-%-%/! \<V]8! $'3;16.'&-%! '%(! 6'$.-&'P#.! -%! 6.'&-%20!




&20123! -*$+'#0-'! +')#! ;##%! 2%(#3&'5#%8! $10;-%-%/! -&! 7-&+! &3#'&0#%&*! &'3/#&-%/!
+461P-'9!T%!)-)1!*&2(-#*8!2*-%/!'!\'A:!023-%#!&20123!01(#.8!+')#!*+17%!#%+'%$#(!
&20123! /317&+! (#.'4! 7-&+! &+#! '((-&-1%! 1,! &+#! ;-13#(2$&-)#! $4&1&1P-$! '/#%&*!
&-3'6'c-0-%#! 13! ;'%1P'%&31%#! D<qVAH! &1! \<V]! D:1c#3! #&! '.98! I@@EH9! \10;-%-%/!
3'(-1-002%1&+#3'64! 7-&+! )'*$2.'3! (-*326&-1%! +'*! '.*1! *+17%! #'3.4! 6310-*#9! T%!
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1.4 Combining radiotherapy and vascular 
directed therapy  
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$106'3'&-)#.4!*.17#3!&+'%!-%!%1%[-33'(-'&#(!*-&#*9!<!*&2(4!#P'0-%-%/!&+#!#,,#$&*!1%!
='X2!P#%1/3',&*!(#01%*&3'&#(! ,23&+#3!/317&+! -%+-;-&-1%!;4! &+#!'((-&-1%!1,! &+#!'%&-[
'%/-1/#%-$!'/#%&!]:`KEKk!m`III?EV8!7+#3#'*!&+-*!$10;-%'&-1%!(-(!%1&!*-/%-,-$'%&.4!
(#.'4!&20123!/317&+!-%!&+#!*'0#!&20123*!-06.'%&#(!'&!'!%1%[-33'(-'&#(!*-&#!Dm-6*!#&!
'.98! I@@?H9! BYJ=! -*! '%! -0613&'%&! #%(1&+#.-'.! $#..! *23)-)'.! ,'$&138! -&*! 7-&+(3'7'.!
-%(2$#*!$#..!(#'&+!'%(! -&!+'*!'!631&#$&-)#! 31.#! -%! &20123!;.11(!)#**#.*8!+#.6-%/! &1!
$12%&#3'$&! &+#!*#N2#.'#!1,!3'(-1&+#3'649! T%&#3326&-1%!1,! &+-*!631&#$&-)#!0#$+'%-*08!
;4! &+#! $10;-%#(! 3'(-1&+#3'64! '%(! '%/-1/#%#*-*! -%+-;-&-1%8! 3#*2.&*! -%! -%$3#'*#(!
#%(1&+#.-'.! $#..! '616&1*-*b! &+#! -%+-;-&-1%! 1,! &+#! *-/%'..-%/! $'*$'(#! -%(2$#(! ;4!
'%/-1/#%-$!,'$&13*8!-%$.2(-%/!BYJ=8!(-3#$&.4!3'(-1*#%*-&-*-%/!&20123!#%(1&+#.-'.!$#..*!
DJ13*5-! #&! '.98! >CCCH9! <616&1*-*! -*! &+#! 0'-%! (#'&+! 6'&+7'4! ,13! #%(1&+#.-'.! $#..*!




'%1&+#3! 61&#%&-'.! )'*$2.'3! *&3'&#/4! &1! #%+'%$#! &+#! #,,#$&*! 1,! 3'(-1&+#3'649! :+-*!
)'*$2.'3!%130'.-*'&-1%!+'*!;##%!*+17%! &1! -%$3#'*#! &20123!1P4/#%'&-1%!'%(8!'*!'!
$1%*#N2#%$#! 1,! &+-*8! -%$3#'*#! &20123! 3'(-1*#%*-&-)-&4! DU-%5.#3! #&! '.98! I@@VH9!






\10;-%#(! '%/-1/#%#*-*! -%+-;-&-1%! '%(! 3'(-1&+#3'64! $'%! '.*1! 631(2$#! #%+'%$#(!
#,,#$&*!1%!(-*&'%&!0#&'*&'*#*!-%!'((-&-1%!&1!&+#!#,,#$&*!*##%!'&!&+#!63-0'34!*-&#9!!:+#!
#,,#$&!1,!'((-%/!&+310;1*61%(-%[>!D:R][>H!&1!*-%/.#!,3'$&-1%!3'(-1&+#3'64!+'*!;##%!
.115#(! '&! 2*-%/! &+#! +20'%! 0#.'%10'! P#%1/3',&! X>I! D"1,*&'(! #&! '.98! I@@GH9!
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mXFVKV8! 7+-$+! -%+-;-&*! ;1&+! YJ="! '%(! BYJ="[I8! +'*! ;##%! #)'.2'&#(! -%!
$10;-%'&-1%!7-&+!3'(-1&+#3'649!T%!'!*&2(4!7-&+!,3'$&-1%'&#(!3'(-1&+#3'64!DI@J4k!>@vk!
I7##5*H!2*-%/!&+#!W:IC!$1.1%!$'3$-%10'!P#%1/3',&!01(#.8!mXFVKV8!I?0/k5/8!7'*!
13'..4! D691H! '(0-%-*&#3#(! ('-.48! ,-)#! ('4*! 6#3! 7##5! ,13! &71! 7##5*! #-&+#3!
%#1'(_2)'%&.48! $1%$233#%&.4! 13! '(_2)'%&.4! DL3'c#..#! #&! '.98! I@@FH9! <%! '((-&-)#!
;#%#,-$-'.!#,,#$&!7'*!*##%!7-&+!&+#!$10;-%'&-1%!&+#3'648!;2&!&+-*!7'*!-%(#6#%(#%&!1,!
&+#! &-0-%/! 1,! mXFVKV9! ! R-0-.'3.48! -%! '! *&2(4! 7-&+! ('-.4! mXFVKV8! G@0/k5/! 6919! -%!
$10;-%'&-1%!7-&+!3'(-1&+#3'64!D>IJ4kVvkI7##5*H8!'!;#%#,-$-'.!#,,#$&8!-%(#6#%(#%&!1,!
*#N2#%$#8! 7'*! 1;*#3)#(! -%! &+#! YJ="[61*-&-)#! +#'(! '%(! %#$5! *N2'012*! $#..!
$'3$-%10'! P#%1/3',&8! laR\\Ib! '.&+12/+! $1%$233#%&! '(0-%-*&3'&-1%! +'(! *26#3-13!
'%&-[&20123! '$&-)-&4! $106'3#(! &1! '(_2)'%&! &3#'&0#%&! -%! &+#! YJ="[%#/'&-)#!
P#%1/3',&8! laR\\>@! DJ2*&',*1%! #&! '.98! I@@EH9! :+#*#! ,-%(-%/*! '3#! -%! $1%&3'*&! &1!
&+1*#! 1,! '! ,23&+#3! *&2(48! 7+#3#! &+#! \'M2! F! AR\M\! P#%1/3',&! 7'*! 2*#(! -%!







L#%#,-$-'.! '%&-[&20123! '$&-)-&4! +'*! '.*1! ;##%! 3#613&#(! -%! 63#$.-%-$'.! *&2(-#*8!
$10;-%-%/! mXFVKV! 7-&+! $1%$233#%&! $+#013'(-'&-1%! 2*-%/! &#01c1.'0-(#! -%!
0'.-/%'%&! /.-10'! P#%1/3',&*! '%(! 7-&+! /#0$-&';-%#! -%! 6'%$3#'&-$! $'3$-%10'!
P#%1/3',&*8!DQR'%(*&3x0!#&!'.98!I@@ES8!QL-'%$1!#&!'.98!I@@FSH9!Z&+#3!$10;-%'&-1%*!&+'&!
+')#! *+17%! 6310-*#! -%! 63#$.-%-$'.! *&2(-#*! -%$.2(#! #3.1&-%-;8! ;#)'$-c20';! '%(!
3'(-1&+#3'64!'%(!'.*1!*2%-&-%-;8!$#&2P-0';!'%(!3'(-1&+#3'64b!;1&+!*&2(-#*!2*#(!&+#!
*'0#! ,3'$&-1%'&#(! 3'(-1&+#3'64!*$+#(2.#! DIVJ4kVvk>9?7##5*H!'%(!*'0#!+#'(!'%(!
%#$5!$'%$#3!P#%1/3',&8!\<MGG! DQL1c#$!#&!'.98!I@@ES8! QL1c#$!#&!'.98!I@@CSH9!\.-%-$'.!
&3-'.*! '3#! '7'-&#(! &1! #*&';.-*+! 7+#&+#3! &+-*! (2'.! &'3/#&-%/! 1,! YJ="! '%(! BYJ=! -%!
$10;-%'&-1%! 7-&+! 3'(-1&+#3'64! $'%! 631(2$#! &+-*! #%+'%$#(! '%&-[&20123! '$&-)-&4! -%!
+20'%*8! -%!'((-&-1%!&1!(#&#30-%-%/!&+#!-06'$&!1,!*$+#(2.-%/!1%!&+-*!$10;-%'&-1%!-%!
(-,,#3#%&! &20123! &46#*8! /-)#%! &+#! )'3-';.#! #,,#$&*! *##%! -%! &+#! 63#$.-%-$'.! &3-'.*!7-&+!
(-,,#3#%&!&20123*9!
!
YJ="! -%+-;-&13*!+')#!;##%! .115#(!'&! -%!$10;-%'&-1%!7-&+!BX<*!'%(! 3'(-1&+#3'649!
J#,-&-%-;!+'*!;##%!$10;-%#(!7-&+!mXF>IF!'%(!,3'$&-1%'&#(!3'(-1&+#3'648!>FJ4!-%!V!
,3'$&-1%*!1)#3!I!7##5*8!-%!&+#!AR\M\!P#%1/3',&!01(#.8!<?VC!D"';#%!#&!'.98!I@@VH9!
mXF>IF! 7'*! /-)#%! 7##5.4! '&! '! (1*#! 1,! >?@0/k5/! -969! ',&#3! &+#! $106.#&-1%! 1,!
3'(-1&+#3'64!#'$+!7##5!'%(!/#,-&-%-;!7'*!/-)#%!'&!'!(1*#!1,!>@@0/k5/!('-.4! ,13!I!
7##5*9!:+-*! &3-6.#!$10;-%'&-1%!1,! 3'(-1&+#3'648!/#,-&-%-%-;!'%(!mXF>IF!*-/%-,-$'%&.4!
-%$3#'*#(! &20123! /317&+! (#.'4! $106'3#(! &1! 3'(-1&+#3'64! '%(! #-&+#3! /#,-&-%-;! 13!
mXF>IF!'.1%#9!
!
1.4.4.3  NOS inhibition 
=1..17-%/! #)-(#%$#! *+17-%/! #%+'%$#0#%&! 1,! &+#! )'*$2.'3! #,,#$&*! 1,!BX<*! ;4! &+#!
'((-&-1%!1,!AZR!-%+-;-&-1%8!&+#!$10;-%'&-1%!1,!&+#*#!&71!)'*$2.'3!(-3#$&#(!&+#3'6-#*!
+'*! ;##%! .115#(! '&! -%! $10;-%'&-1%! 7-&+! *-%/.#! ,3'$&-1%! 3'(-1&+#3'649! T%! '! *&2(4!
.115-%/! '&! &+#! $10;-%'&-1%! 1,! mXF>IF! '%(! 3'(-1&+#3'648! %-&3-$! 1P-(#! *4%&+'*#!
 68
-%+-;-&-1%! 7'*! -%$13613'&#(! -%&1! &+#! *$+#(2.#8! '*! &+#! lEK! /.-1;.'*&10'! 01(#.! -*!
5%17%! &1! ;#! 3#.'&-)#.4! 3#*-*&'%&! &1! &+#! -%(2$&-1%! 1,! &20123! %#$31*-*! ;4! mXF>IF!
DU'$+*;#3/#3! #&! '.98! I@@?H9! ! :+#! '((-&-1%! 1,! M[AA<! DI@0/k5/H! &1! mXF>IF!
DI@@0/k5/H8! ;1&+! /-)#%! -9698! -%$3#'*#(! &+#! 6#3$#%&'/#! 1,! %#$31*-*! 631(2$#(! '&! IV!
+123*!61*&! &3#'&0#%&! &1!EC! &1!C?n8!$106'3#(!7-&+!>@! &1!GEn!7-&+!mXF>IF!'.1%#9!
W17#)#3!&+-*!$10;-%'&-1%!1,!M[AA<!'%(!mXF>IF8!7+#%!/-)#%!',&#3!'!*-%/.#!>@J4!1,!
3'(-1&+#3'648! (-(! %1&! *+17!'%4!'((-&-1%'.! ;#%#,-&! $106'3#(!7-&+! 3'(-1&+#3'64!'%(!
mXF>IF!'.1%#9!
 
1.5  Functional imaging 
>9?9>! :+#! 31.#!1,! ,2%$&-1%'.! -0'/-%/! -%!'**#**-%/! 3#*61%*#!
&1!)'*$2.'3!(-3#$&#(!&+#3'6-#*!
<*! &+#! &3'%*-&-1%! ,310! $1%)#%&-1%'.! $'%$#3! &3#'&0#%&*! &1!013#! &'3/#&#(! &+#3'6-#*!
#)1.)#*8!N2#*&-1%*!+')#!'3-*#%!3#/'3(-%/!&+#!;#*&!7'4!&1!'**#**!&20123!3#*61%*#9!
:+#!U13.(!W#'.&+!Z3/'%-*'&-1%!62;.-*+#(!&+#!UWZ!+'%(;115!,13!3#613&-%/!3#*2.&*!1,!
$'%$#3! &3#'&0#%&! -%! >CKC8! 7-&+! &+#! '-0! 1,! 631)-(-%/! '! *&'%('3(! '%(! 3#631(2$-;.#!
0#'%*!,13!&+#!'**#**0#%&!1,!&20123!3#*61%*#9!X#*6-&#!&+#!7-(#*63#'(!'(16&-1%!1,!
&+#*#! $3-&#3-'8! 2*-%/! &+#! 0#'*23#0#%&! 1,! &20123*! 7-&+! 02.&-6.-$'&-1%! 1,! &71!
0#'*23#(! (-'0#&#3*8! &+#4! 7#3#8! 2.&-0'&#.48! ,#.&! &1! ;#! $20;#3*10#! '%(!
2%%#$#**'3-.4!$106.#P9!:+-*! .#(! &1! &+#!*2;*#N2#%&!(#)#.160#%&!1,! &+#! f"#*61%*#!
Y)'.2'&-1%! \3-&#3-'! -%! R1.-(! :20123*! D"Y\TR:HO! D:+#3'**#! #&! '.98! I@@@H9! :+#!
'**#**0#%&! 631$#**!7'*! *-/%-,-$'%&.4! *-06.-,-#(8!7-&+! 1%.4! &+#! .1%/#*&! (-'0#&#3! 1,!
&+#! &20123! 3#N2-3#(8! 7+-.*&! 0'-%&'-%-%/! '! .#)#.! 1,! '$$23'$4! '%(! 3#631(2$-;-.-&49!
"Y\TR:! +'*! *-%$#! ;##%! ,23&+#3! 26('&#(! '%(! *-06.-,-#(! DY-*#%+'2#3! #&! '.98! I@@CH9!
U+-.*&! =XJ[]Y:! -(#%&-,-$'&-1%! 1,! %#7! .#*-1%*! -*! %17! '$$#6&#(! '*! #)-(#%$#! 1,!
631/3#**-)#! (-*#'*#8! &20123! *-c#! 3#0'-%*! &+#! 0'_13! $1061%#%&! &1! "Y\TR:8!
61&#%&-'..4! .-0-&-%/! -&*! 2*#! -%! '**#**-%/! %#7#3! &'3/#&#(! '/#%&*9! :20123! *+3-%5'/#!
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0'4! 3#,.#$&! '! *2;*&'%&-'.! #,,#$&8! ;2&! -&! $'%%1&! '$$23'&#.4! 3#,.#$&! '$2&#! ,2%$&-1%'.!
$+'%/#*! 7-&+-%! &+#! &201239! \1%)#3*#.48! *-/%-,-$'%&! '%&-[&20123! #,,#$&! $'%! 1$$23!
7-&+12&!*-/%-,-$'%&!&20123!*+3-%5'/#!1$$233-%/9!:+#3#!-*!-%+#3#%&!1;*#3)'&-1%'.!#3313!
-%!&+#!0#'*23#0#%&!1,!&20123*!'%(!-&!$'%!;#!#P&3#0#.4!(-,,-$2.&!&1!0#'*23#!&+#!,2..!





2.&3'*12%(! +')#! $10#! &1! &+#! ,13#,31%&9! :+#! ';-.-&4! 1,! &+#*#! %1)#.! &#$+%-N2#*! &1!
'**#**!*2;&.#!'$2&#!0-$31$-3$2.'&134!$+'%/#*!+'*!;##%!1,!6'3&-$2.'3! -0613&'%$#! -%!
;1&+!&+#!(-'/%1*&-$!*#&&-%/!'%(!&+#3'6#2&-$!01%-&13-%/!1,!&20123*9!:+#*#!&#$+%-N2#*!
$'%! ;#! 2*#(! &1! 631)-(#! 3#.-';.#! ;-10'35#3*! ,13! &+#! 01%-&13-%/! 1,! '%&-$'%$#3!
&+#3'6-#*8!#*6#$-'..4!'%&-['%/-1/#%-$!'%(!)'*$2.'3!(-*326&-)#!*&3'&#/-#*8!;1&+! -%! &+#!
$.-%-$'.! &3-'.*! *#&&-%/! '%(! '.*1! -%! #)#34('4! $.-%-$'.! 63'$&-$#9! :+#! $+'3'$&#3-*&-$!
,#'&23#*! 1,! &20123! )'*$2.'&23#! '3#! (-*&-%/2-*+';.#! ,310! &+#! )'*$2.'3! 6'&&#3%*!
1;*#3)#(! -%!%1%[0'.-/%'%&! &-**2#9!a'%4!1,! &+#! ,#'&23#*!'3#!'0#%';.#! &1!*&2(4!;4!






:+#! 2*#! 1,! 3'6-(! *#N2#%$#! 6#3,2*-1%! 13! (4%'0-$! $1%&3'*&[#%+'%$#(! DX\YH!
$1062&#(! &101/3'6+4! D\:H! -%! &+#! '**#**0#%&! 1,! &-**2#! )'*$2.'&23#! 7'*! ,-3*&!
3#613&#(!-%!>CE@8!-%!'!*&2(4!1,!-%&3'$3'%-'.!;.11(!)1.20#!D<P#.8!>CE@H9!=1..17-%/!1%!







1,! &+#!3'&#!1,!#%+'%$#0#%&! -%!#'$+!6-P#.! Da-.#*!#&!'.98!>CC>H9!\.-%-$'.!*&2(-#*!+')#!
*-%$#!;##%!2%(#3&'5#%!2*-%/!X\Y[\:!,13!N2'%&-,-$'&-1%!1,!&-**2#!;.11(!)1.20#!'%(!
'*!'!0#'*23#!1,!6#3,2*-1%! -%! &+#!5-(%#48! .-)#3!'%(!6'%$3#'*9!=23&+#3!3#,-%#0#%&!1,!
X\Y[\:! '%(! -%$3#'*#(! 61&#%&-'.! '66.-$'&-1%*! ,13! &+#*#! &#$+%-N2#*! +')#! 3#*2.&#(!
,310! &+#!(#)#.160#%&!1,!02.&-[(#&#$&13! DaXH!\:*9!aX\:!'..17*! &+#!*-02.&'%#12*!




\:9! :+-*! -*! &+#%! ,1..17#(! ;4! &+#! '(0-%-*&'&-1%! 1,! '%! -9)9! $1%&3'*&! '/#%&! '%(! &+#!
'$N2-*-&-1%! 1,! '! *#3-#*! 1,! ,23&+#3! \:*9! :+#! 3#*2.&'%&! #%+'%$#0#%&! 1,! &-**2#! -*!




.-%#'3! 3#.'&-1%*+-6! ;#&7##%! #%+'%$#0#%&! DW12%*,-#.(! l%-&*! QWlSH! '%(! -1(-%#!









-%! #)#34('4! $.-%-$'.! 63'$&-$#! 7-&+! (-'/%1*&-$! \:! '%(! '3#! -1(-%#! ;'*#(8! 2*2'..4!
(#3-)'&-)#*!1,!-1(1;#%c1-$!'$-(8!7-&+!'!01.#$2.'3!7#-/+&!1,!'312%(!K@@X'9!:+-*!&46#!
1,!$1%&3'*&!3#0'-%*!-%!&+#!-%&3')'*$2.'3!$106'3&0#%&!,13!&+#!,-3*&!,#7!$'3(-'$!$4$.#*!
61*&! -%_#$&-1%! &+#%!(-,,2*#*! -%&1! &+#!#P&3')'*$2.'3[#P&3'$#..2.'3!*6'$#8!7-&+!0-%-0'.!
-%&3'$#..2.'3!26&'5#!Dr>nH9!T&!-*!#P$3#&#(!0'-%.4!)-'!&+#!5-(%#4*8!'.&+12/+!&+#3#!$'%!
;#! '! $1061%#%&! 1,! +#6'&1[;-.-'34! #P$3#&-1%! &119! a'$3101.#$2.'3! '/#%&*! +')#! '!
02$+!/3#'&#3!3#&#%&-1%!7-&+-%!&+#!-%&3')'*$2.'3!*6'$#8!7-&+!r>n!,-3*&!6'**!#P&3'$&-1%8!
'..17-%/!'!013#!'$$23'&#!'**#**0#%&!1,! )'*$2.'3! )1.20#9!<*! &20123!)'*$2.'&23#8!
;2&!%1&!%130'.! &-**2#!)'*$2.'&23#8! -*!6#30#';.#! &1! &+#*#!0'$3101.#$2.#*8! &+#3#! -*!
&+#! 61&#%&-'.! ,13! &+-*! &1! ;#! #P6.1-&#(! 2*-%/! &+-*! &46#! 1,! $1%&3'*&! -%! 6#3,2*-1%! \:9!
\233#%&.4! &+#*#! '/#%&*8! (#*6-&#! *+17-%/! 6310-*#! -%! 63#$.-%-$'.! &3-'.*8! '3#! %1&!
.-$#%*#(! ,13! $.-%-$'.! 2*#! '%(! 3#*2.&*! ,310! $.-%-$'.! &3-'.*! '3#! '7'-&#(! DR-01%! #&! '.98!
I@@?H9!
!
<! %20;#3! 1,! 0'&+#0'&-$'.! 01(#..-%/! &#$+%-N2#*! +')#! ;##%! 2*#(! -%! X\Y[\:! &1!
*&2(4!(-,,#3#%&!)'*$2.'3!6'3'0#&#3*9!<%'.4*-*!0#&+1(*!;'*#(!1%! &+#!=-$5!63-%$-6.#!
+')#! ;##%! $1001%.4! 2*#(! &1! '**#**! ;.11(! ,.17! 6#3! &-**2#! )1.20#! D'.*1! &#30#(!
6#3,2*-1%H8! -%$.2(-%/! &+#! f6#'5O!0#&+1(!13! &+#! f*.16#O!0#&+1(! DQa2..'%-! '%(!J12.(8!
>CEGS8! Qa-.#*!>CC>SH9!X2'.!$106'3&0#%&!01(#..-%/!+'*!;##%!2*#(8!;'*#(!261%!'%!
'%'.4*-*! 0#&+1(! ,13! &+#! 01(#..-%/! 1,! 3'(-1%2$.-(#! &3'$#3! 5-%#&-$*8! +')-%/! ;##%!
'('6&#(!'%(!*-06.-,-#(!,13!2*#!7-&+!\:!DQ]'&.'5!#&!'.98!>CEGS8!Q]'&.'5!'%(!L.'*;#3/8!
>CE?SH9! :+-*8! ]'&.'5! '%'.4*-*8! $'%! ;#! 2*#(! &1! 631)-(#! #*&-0'&#*! 1,! &-**2#! ;.11(!
)1.20#!DLBH!'%(!'.*1!)'*$2.'3!.#'5'/#!D#P&3'$&-1%!,3'$&-1%8!`>H9!:+#!&-**2#!$1%&3'*&!
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1.6 Laboratory techniques for the assessment 
of tumour vasculature and response 
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Table 1.2  
<()'%&'/#*!'%(!(-*'()'%&'/#*!1,!$10;-%-%/!BX<*!'%(!3'(-1&+#3'649!
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BF= blood flow, BV= blood volume, MTT= mean transit time, PS= permeability surface area 
product, K&3'%*= transfer constant, k#6= rate constant, v#= extravascular-extracellular volume 








Materials and Methods 
 
2.1  Preclinical Studies!
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2.3   Imaging Techniques 
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:GK'"/f! 1$P#,! 7,,->!WK''f! )*1$1&*%! 1&',>!KFS!/,+*%-/f!+*##&'$1&*%>!G''f!-,1,+1*)!
0&-12>!:FS''f!6XOc>!SKK''f!'$1)&T>!S:G!T!S:G''F!H*1$#!-D%$'&+!$+Y.&/&1&*%!1&',!
?$)&,-! 7)*'! ($1&,%1! 1*! ($1&,%1! P.1! 0$/! $(()*T&'$1,#D! ;K! /,+*%-/F! H2,! ,%1&),! BH!
(,)7./&*%!/1.-D!0$/! ),(,$1,-!0&12&%!GV!2*.)/!0&12*.1! &%1,)?,%&%R! 1),$1',%1>!./&%R!
&-,%1&+$#!1,+2%&+$#!($)$',1,)/!1*!$##*0!$//,//',%1!*7!',$/.),',%1!),()*-.+&P&#&1DF!
!
U$1$! 0,),! 1)$%/7,)),-! 1*! $! -,-&+$1,-! 0*)L/1$1&*%! 5],*%$)-*>! 6&,',%/! J,-&+$#!
6*#.1&*%/9F!@$+2!(,)7./&*%!/1.-D!+*%/&/1,-!*7!%&%,!2,#&+$#!/+$%/!5*%,!P$/,#&%,!/+$%!
$%-!,&R21! +*%1)$/1!,%2$%+,-!-D%$'&+! /+$%/9! 12$1! ),Y.&),-!(*/1^()*+,//&%R!P,7*),!
Y.$%1&1$1&?,! (,)7./&*%! $%$#D/&/F! X*)! ,$+2! /+$%>! 12,! G''! +*##&'$1,-! $T&$#! &'$R,/!
0,),! ),7*)'$11,->! &%1*! S''! 12&+L! $T&$#! &'$R,/! 7*)! /'$##,)! 1.'*.)/! .%-,)R*&%R!
/.)R&+$#! ),/,+1&*%! $%-! :K''! 12&+L! $T&$#! &'$R,/! 7*)! #$)R,)! 1.'*.)/! ),+,&?&%R!




/+$%/! PD! +*'($)&%R! 12,! (*/&1&*%! *7! 12,! 1.'*.)! 1*! $-Q$+,%1! $%$1*'&+$#! /1).+1.),/F!
H2,%!,$+2!),7*)'$11,-!$T&$#! &'$R,! 7)*'!12,!/$',!(*/&1&*%!$#*%R! 12,!_^$T&/!*7! 12,!
($1&,%1!7)*'!,$+2!*7!12,!%&%,!2,#&+$#!/+$%/!0$/!/$?,-!$/!$!/,($)$1,!/,)&,/!*%!12,!








1.'*.)>! 0,),! #*$-,-! &%1*! 12,! ()*1*1D(,! (,)7./&*%! /*710$),! 56&,',%/9! P$/,-! *%!
8$1#$L! $%$#D/&/F! H2,! $)1,)&$#! &%(.1! 0$/! -,1,)'&%,-! 7)*'! 12,! P*#./! 1)$+L&%R! /+$%!
&'$R,/!7*)!,$+2!($1&,%1f!./&%R!$%!,#,+1)*%&+!+.)/*)!$%-!'*./,>!$!+&)+.#$)!),R&*%!*7!
&%1,),/1! 5AOE9!0$/!(#$+,-!0&12&%! 12,!$*)1$F!"%!$)1,)&$#! 1&',n$11,%.$1&*%!+.)?,!0$/!
R,%,)$1,-! $.1*'$1&+$##D>! $%-! 12&/! &%7*)'$1&*%! 0$/! /$?,-! ./&%R! 12,! /*710$),! 7*)!
/.P/,Y.,%1! $%$#D/&/F!"! /&%R#,>! +,%1)$#! 1.'*.)! #,?,#!0$/! +2*/,%>! $%-!$%!AOE!0$/!




(&T,#! #*+$1&*%! 0&12&%! 12,! 7.%+1&*%$#! '$(! +*)),/(*%-,-! 1*! $! /&%R#,! Y.$%1&1$1&?,!
(,)7./&*%!?$#.,!),/.#1&%R!7)*'!12,!'$12,'$1&+!+$#+.#$1&*%!*7!12,!-$1$!$1!12$1!#*+$1&*%F!
U$1$! 0,),! $%$#D/,-! *%! $! (&T,#^PD^(&T,#! P$/&/! 7*)! $##! #,?,#/! ,%+*'($//&%R! 12,!
1.'*.)F!MD!$'$#R$'$1&%R!-$1$! 7)*'!$##! &%-&?&-.$#!(&T,#/! 7)*'! 12,/,! #,?,#/>!',-&$%!
?$#.,/! 7*)! (,)',$P&#&1D! /.)7$+,! $),$! ()*-.+1! $%-! P#**-! ?*#.',! 0,),! +$#+.#$1,->!
()*-.+&%R!?$#.,/!7*)!02*#,!1.'*.)!+*?,)$R,f!12,/,!?$#.,/!0,),!),+*)-,-!7*)!,$+2!
($1&,%1F! H2./>! 7*)! $##! ($1&,%1/>!',-&$%! ?$#.,/! *7! 1.'*.)! (,)',$P&#&1D! /.)7$+,! $),$!
()*-.+1! $%-! P#**-! ?*#.',! 7*)! 02*#,! 1.'*.)! +*?,)$R,! 0,),! -*+.',%1,-! 7*)!
/.P/,Y.,%1! /1$1&/1&+$#! ,?$#.$1&*%F! H*! -,1,)'&%,! 12,! 1).,! ?$#.,! 7*)! 12,! -&77,),%1!
($)$',1,)/>! 12,!/+$#&%R! 7$+1*)/!./,-! 1*!()*-.+,!$%!$(()*()&$1,! +*#*.)!-&/(#$D! 5$/!
/2*0%!&%!X&R.),!GF:9!0,),!1$L,%!&%!1*!$++*.%1e!M#**-!c*#.',!5'#N:KK'#9>!$!/+$#&%R!
7$+1*)!*7!:K!0$/!./,-! 5&F,F!$!?$#.,!*7!WK!',$%/!$!P#**-!?*#.',!*7!W!'#N:KK'#!*)!
WZ9f! 8,)',$P&#&1D! /.)7$+,! $),$! ()*-.+1! 5'#N:KK'#N'&%9>! $! /+$#&%R! 7$+1*)! *7! G! 0$/!
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"! #*0!-*/,!.%,%2$%+,-!/1.-D!0$/!(,)7*)',-! &%&1&$##D! 1*! &-,%1&7D! 12,! 1.'*.)f! /+$%!
+*^*)-&%$1,/!0,),!%*1,-! 7*)! 12,! 1.'*.)!'&-!(*&%1>!$%-! 12,/,!+*^*)-&%$1,/!./,-! 1*!
(#$%! 12,!/.P/,Y.,%1!-D%$'&+! /1.-DF!X*.)! +*%1&R.*./!/#&+,/!,$+2! ),+*%/1).+1,-! 1*!
[''! 5$/!/2*0%! &%!X&R.),!GFG9!0,),!*P1$&%,-! 12)*.R2! 12,!'&-^(*&%1!*7! 12,! 1.'*.)!
./&%R! 12,! 7*##*0&%R!$+Y.&/&1&*%!($)$',1,)/e!<KLcf!:GK'"/f!-,1,+1*)!0&-12>!:FS''f!
6XOc>!SKK''f!'$1)&T>!S:G!T!S:G''f!:!/,+*%-!&%1,)?$#!7*)!12,!7&)/1!WK!/,+*%-/>!$%-!
G! /,+*%-! &%1,)?$#! 7*)! 12,! %,T1! WK! /,+*%-/F! "+Y.&/&1&*%! +*'',%+,-! S! /,+*%-/!
7*##*0&%R! 12,! /1$)1! *7! &%1)$?,%*./! &%Q,+1&*%! 1*! $##*0! $+Y.&/&1&*%! *7! P$/,#&%,!
.%,%2$%+,-! &'$R,/F!H2,!,%1&),!BH!(,)7./&*%!/1.-D!0$/! ),(,$1,-!0&12&%!GV!2*.)/!
0&12*.1! &%1,)?,%&%R! 1),$1',%1>! ./&%R! &-,%1&+$#! 1,+2%&+$#! ($)$',1,)/! 1*! $##*0!
$//,//',%1!*7!',$/.),',%1!),()*-.+&P&#&1DF!
!
U$1$! 0,),! 1)$%/7,)),-! 1*! $! -,-&+$1,-! 0*)L/1$1&*%! 5],*%$)-*>! 6&,',%/! J,-&+$#!
6*#.1&*%/9F! "%$#D/&/! 0$/! (,)7*)',-! ./&%R! +*'',)+&$#! (,)7./&*%! /*710$),! 5M*-D!
(,)7./&*%>! 6&,',%/9! &%! *)-,)! 1*! *P1$&%! Y.$%1&1$1&?,!',$/.),',%1/! 5P#**-! ?*#.',>!
P#**-! 7#*0>! ',$%! 1)$%/&1! 1&',! $%-! (,)',$P&#&1D! /.)7$+,! $),$! ()*-.+19F! "!
),(),/,%1$1&?,![''!$T&$#!&'$R,!&%!02&+2!12,!1.'*.)!0$/!P,/1!?&/.$#&/,-!0$/!#*$-,-!
&%1*! 12,! /*710$),F! "! ()*+,//&%R! 12),/2*#-! P,10,,%! ^:SK! 1*! o:SK! a*.%/7&,#-! .%&1/!
5a39!0$/!+2*/,%!1*!*(1&'&/,!/*71!1&//.,!?&/.$#&/$1&*%F!"%!$)1,)&$#!&%(.1!0$/!-,7&%,-!
PD! (#$+&%R! $! +&)+.#$)! ),R&*%! *7! &%1,),/1! 5AOE9>! :K''G! &%! /&_,>! 0&12&%! 12,! P,/1^
?&/.$#&/,-! $)1,)D! *%! 12,! /,#,+1,-! &'$R,f! 12,! +*''*%>! &%1,)%$#! *)! ,T1,)%$#! +$)*1&-!







',$/.),',%1/! 0,),! *P1$&%,-! PD! ./&%R! $!'*./,! $%-! ,#,+1)*%&+! +.)/*)! 1*! 1)$+,! $!
7),,2$%-!AOE!$)*.%-! 12,! 1.'*.)!'$)R&%/F!B$),!0$/! 1$L,%! 1*!,T+#.-,!/.))*.%-&%R!
$&)!*)!.%&%?*#?,-!%,&R2P*.)&%R!P#**-!?,//,#/F!J,$%!?$#.,/!7*)!P#**-!?*#.',>!P#**-!
7#*0>!1)$%/&1!1&',!$%-!(,)',$P&#&1D!/.)7$+,!$),$!()*-.+1>!7*)!12&/!),(),/,%1$1&?,!S''!
$T&$#! /,+1&*%>! 0,),! ),+*)-,-! 7*)! ,$+2! &%-&?&-.$#F! 8,$L! ,%2$%+,',%1! $%-! 1&',! 1*!
(,$L!,%2$%+,',%1!-,)&?,-! 7)*'! 12,! ),/.#1&%R!,%2$%+,',%1!+.)?,/!0,),! ),+*)-,-!
$#/*!7*)! 12,!$)1,)&$#! &%(.1!?,//,#!$%-!7*)! 12,!1.'*.)F!"%$#D/&/!0$/!),(,$1,-!7*)! 12,!





















$9! O)&R&%$#!-$1$!wCV = wSD/mean!
P9! ln 1)$%/7*)',-!-$1$!wCV = Exp(wSD)-1 
V9! A,(,$1$P&#&1D!($)$',1,)!5r9!
$9! O)&R&%$#!-$1$!r% = (r/mean) x 100!
P9! ln!1)$%/7*)',-!-$1$!r% = [100x Exp(ln mean ± r)]/mean 
S9! c$)&$%+,! )$1&*! 5F9e! 12,! )$1&*!*7! 12,!P,10,,%!($1&,%1! ?$)&$%+,!$%-!0&12&%!($1&,%1!
?$)&$%+,!p![Xn2/n]/[Xd2/d]f!02,),!n!&/!12,!%.',)$1*)!$%-!d!&/!12,!-,%*'&%$1*)F!
E%1)$+#$//! +*)),#$1&*%! +*,77&+&,%1! 5ICC9! p! mSSB – SS! T/ (m-1)SSTf! 02,),! m! &/! 12,!




"##! ($1&,%1/! &%! 12,!UB@^BH!].%R! 1.'*.)! +*%1)*#! R)*.(!.%-,)0,%1! )*.1&%,!8@H^BH!
/1$R&%R>! 1*! -,1,)'&%,! 12,&)! /.&1$P&#&1D! 7*)! )$-&+$#! /.)R&+$#! ),/,+1&*%F:<XUC^8@HN!BH!
0$/!(,)7*)',-!$/!7*##*0/>!$++*)-&%R!1*!12,!/1$%-$)-!()*1*+*#!*7!12,!8$.#!61)&+L#$%-!
6+$%%,)! B,%1),>! J*.%1! c,)%*%! a*/(&1$#>! I*)120**->! J&--#,/,T>! 34F! X$/1,-!
($1&,%1/!),+,&?,-!$%!&%1)$?,%*./!&%Q,+1&*%!*7!VFSJMYNLR!:<XUCF!X*##*0&%R!$!=K!1*!;K!
'&%.1,!.(1$L,!(,)&*->!&'$R&%R!0$/!(,)7*)',-!*%!$%!&%1,R)$1,-!8@HN!BH!&%/1).',%1!
&%+*)(*)$1&%R! $! V! *)! =V^/#&+,! JUBH! 5U&/+*?,)D! ]6! *)! U&/+*?,)D! cBH>! C@!
a,$#12+$),>! B2$#7*%1! 61! C&#,/>! 349F! BH! 7*)! $11,%.$1&*%! +*)),+1&*%! 0$/! (,)7*)',-!
7)*'!12,!/L.##!P$/,!1*!.((,)!12&R2e!:VKLc>!<K'">!(&1+2!:FS>!WF[S''!-,1,+1*)/F!H2,!
8@H!/+$%!0$/!*P1$&%,-!*?,)!12,!/$',!$%$1*'&+$#!$),$!$/!BHF!"##!$+Y.&/&1&*%/!0,),!
+$))&,-! *.1! &%! GU! '*-,>! +*%/&/1&%R! *7! $%! ,'&//&*%! /+$%! *7! V! '&%.1,/! (,)! P,-!
(*/&1&*%F! 8@H! &'$R,/! 0,),! ),+*%/1).+1,-! ./&%R! BH! 7*)! $11,%.$1&*%! +*)),+1&*%! PD!
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,'(#*D&%R!BH!'$(/F!H)$%/$T&$#!,'&//&*%! &'$R,/!*7!WF;!T!WF;!T!VFGS''!5&%!(#$%,!
'$1)&T! /&_,! :G<! T! :G<9! 0,),! ),+*%/1).+1,-! ./&%R! *)-,),-! /.P/,1/! ,T(,+1$1&*%!
'$T&'&/$1&*%!5O6@J9!0&12!10*!&1,)$1&*%/!$%-!G<!/.P/,1/F!H2,!$T&$#!7&,#-!*7!?&,0!0$/!
:V<F[S''F! E'$R,/! 0,),! ?&,0,-! *%! $! /1$%-$)-! ),(*)1&%R! 0*)L/1$1&*%! 5"-?$%1$R,!
VFV>!C@!a,$#12+$),>!B2$#7*%1!61!C&#,/>!349F!"!),+1$%R.#$)!?*#.',!*7! &%1,),/1!5cOE9!
0$/! (#$+,-! *?,)! 12,! ,%1&),! 1.'*.)F! H2,! /1$%-$)-! .(1$L,! ?$#.,! 563c'$T>!
63c',$%9! P$/,-! *%! $! /1$%-$)-! (),^-,7&%,-! 8@H^12),/2*#-! *7! VGZ! 0$/! -,)&?,-!
$.1*'$1&+$##D!7*)!12,!1.'*.)!cOEF!
!
2.4  ELISA 
M#**-!/$'(#,/!0,),!1$L,%!$1!V!1&',!(*&%1/!7*)!12,/,!1,/1/!12)*.R2!12,!+*.)/,!*7!12&/!
/1.-De!8)&*)!1*!7&)/1!B"V8!$-'&%&/1)$1&*%!5U$D!S9f!V!2*.)/!(*/1!B"V8!$-'&%&/1)$1&*%!
5U$D! S9f! =! 1*! <! 2*.)/! (*/1! B"V8! $-'&%&/1)$1&*%! 5U$D! S9f! [! -$D/! (*/1! B"V8!
$-'&%&/1)$1&*%! 5U$D!:G9F!"1!,$+2!/,#,+1,-! 1&',!(*&%1! ?,%,(.%+1.),!0$/!(,)7*)',-!
$%-! *%,! S'#! @UH"! P#**-! 1.P,! 7&##,-F! E'',-&$1,#D! $71,)! +*##,+1&*%>! 12,! 1.P,! 0$/!
&%?,)1,-!1*!'&T!12,!$%1&+*$R.#$%1!$%-!P#**-!$-,Y.$1,#D>!12,%!12,!/$'(#,!0$/!(#$+,-!
*%! &+,! &%! $! +#*/,-! +*%1$&%,)F! `&12&%! :S! '&%.1,/! *7! +*##,+1&*%! 12,! @UH"! 1.P,!
+*%1$&%&%R! 12,!P#**-!/$'(#,!0$/!+,%1)&7.R,-! 7*)!:S!'&%.1,/!$1!:KKKT!R>!$1!GqB! 1*!
[qB>! 1*! /,($)$1,! *.1! 12,! (#$/'$F! X*##*0&%R! 12&/! 12,! (#$/'$! 0$/! &'',-&$1,#D!
$#&Y.*1,-! ,Y.$##D! &%1*! W! (*#D()*(D#,%,! /+),0! +$((,-! +)D*R,%&+! ?&$#/f! 12,! ?&$#/!
2$?&%R!P,,%!#$P,##,-!0&12!12,!()*1*+*#!%.'P,)>!/.PQ,+1!EU>!1&',!(*&%1>!-$1,!$%-!1&',!
*7!/$'(#&%RF!H2,!?&$#/!0,),!12,%!(#$+,-!&%!$!+*%1$&%,)!1*!(),?,%1!#&R21!),$+2&%R!12,!






X*##*0&%R! +*##,+1&*%! *7! $##! ),Y.&),-! /$'(#,/>! $))$%R,',%1/! 0,),! '$-,! 0&12! 12,!
$%$#D1&+$#!#$P*)$1*)D!7*)!/2&((&%RF!"##!/$'(#,/!0,),!+*.)&,),-!*%!-)D!&+,!1*!I$1&*%$#!
M#**-! 6,)?&+,! 5Ia6MH9! &%! OT7*)->! 02,),! 12,D! 0,),! 1,/1,-! ./&%R! AoU! 6D/1,'/!
m.$%1&L&%,r!B*#*)&',1)&+!6$%-0&+2!@]E6"!4&1/F!@$+2!L&1!+*%1$&%,-e!(),^+*$1,-!;=^
0,##!'&+)*(#$1,>! +*%Q.R$1,-! -,1,+1&*%! $%1&P*-D>! +$#&P)$1,-! &''.%*$//$D! /1$%-$)->!
$//$D! -&#.,%1>! +$#&P)$1*)! -&#.,%15/9>! 0$/2! P.77,)>! +*#*.)! ),$R,%1! "! $%-! M>! /1*(!
/*#.1&*%!$%-!(#$1,!/,$#,)/F!!
!
H2,! +D1*L&%,/! 1,/1,-! 7*)! 0,),! 6UX^:>! c@CX>! c@CXA^:! $%-! C^B6XF! H2,! $//$D/!
,'(#*D,-! ./,-! $! Y.$%1&1$1&?,! /$%-0&+2! ,%_D',! &''.%*$//$D! 1,+2%&Y.,F! "!
'*%*+#*%$#!$%1&P*-D!/(,+&7&+!7*)!12,!+D1*L&%,!1*!P,!&-,%1&7&,-!0$/!(),^+*$1,-!*%1*!$!
'&+)*(#$1,F! 61$%-$)-/! $%-! /$'(#,/! 0,),! 12,%! (&(,11,-! &%1*! 12,! 0,##/>! 0&12! 12,!
&''*P&#&_,-!$%1&P*-D!P&%-&%R!$%D!*7!12,!1$)R,1!+D1*L&%,!(),/,%1F!"71,)!0$/2&%R!$0$D!
$%D! .%P*.%-! /.P/1$%+,/>! $%! ,%_D',^#&%L,-! (*#D+#*%$#! $%1&P*-D! /(,+&7&+! 7*)! 12,!
+D1*L&%,! 0$/! $--,-! 1*! 12,! 0,##/F! X*##*0&%R! $! 0$/2! 1*! ),'*?,! $%D! .%P*.%-!
$%1&P*-D^,%_D',! ),$R,%1>! $! /.P/1)$1,! /*#.1&*%! 0$/! $--,-! 1*! 12,! 0,##/! 1*! $##*0!
+*#*.)! 1*!-,?,#*(! &%!()*(*)1&*%! 1*! 12,!$'*.%1!*7!+D1*L&%,!P*.%-! &%! 12,! &%&1&$#! /1,(F!
H2,!+*#*.)!-,?,#*(',%1!0$/!/1*((,-!$%-!12,!&%1,%/&1D!*7!12,!+*#*.)!',$/.),-!./&%R!
$!'&+)*(#$1,!),$-,)!1*!-,1,)'&%,!12,!*(1&+$#!-,%/&1D!*7!,$+2!0,##F!H2,!0$?,#,%R12!7*)!
12&/! ),$-,)! 0$/! /,1! 1*! SVK%'! *)! S[K%'>! .%#,//! 0$?,#,%R12! +*)),+1&*%! 0$/!
.%$?$&#$P#,! 02,%! $! /.P1)$+1&*%! 0$/! (,)7*)',-! 1*! +*)),+1! 7*)! 12,! *(1&+$#!
&'(,)7,+1&*%/!&%!12,!(#$1,F!!
!
H*! +$#+.#$1,! 12,! ),/.#1/>! *(1&+$#! -,%/&1D! 7*)! 12,! /1$%-$)-/! 0$/! (#*11,-! ?,)/./! 12,!
+*%+,%1)$1&*%! *7! 12,! /1$%-$)-/>! 0&12! 12,! P,/1! +.)?,! -)$0%F! H2,! -$1$! .%-,)0,%1!
#*R$)&12'&+!1)$%/7*)'$1&*%!1*!7$+&#&1$1,!()*-.+1&*%!*7!$!#&%,$)!(#*1!$%-!$#/*!),R),//&*%!
$%$#D/&/F! E%! *)-,)! 1*! -,1,)'&%,! 12,! +*%+,%1)$1&*%! *7! 12,! /(,+&7&+! +D1*L&%,! 7*)! ,$+2!
/$'(#,>! 12,! $P/*)P$%+,! ?$#.,! *%! 12,! D^$T&/! 0$/! 7*.%-! $%-! $! 2*)&_*%1$#! #&%,!
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"1! /.)R,)D! 12,! #.%R! *)! #.%R! #*P,5/9! +*%1$&%&%R! 12,! 1.'*.)! 0,),! ,T+&/,-! $%-!
&'',-&$1,#D! (#$+,-! &%! 7*)'$#&%F! X*##*0&%R! 1)$%/7,)! 1*! 12,! ($12*#*RD! #$P*)$1*)D! 12,!
/(,+&',%/!0,),!12,%!),&%7#$1,-!&%!7*)'$#&%!7*)!GV!1*!V<!2*.)/>!$##*0&%R!12,!/(,+&',%!
1*! P,! +.1! $%-! $//,//,-! &%! 12),,! -&',%/&*%/F! H2,! ),&%7#$1,-! /(,+&',%! 0$/!
*)&,%1$1,->!&%1*!12,!/$',!(#$%,!12$1!&1!0*.#-!2$?,!,T&/1,-!&%!/&1.>!$%-!12,%!12,!02*#,!
/(,+&',%!0$/! +.1! &%1*! S! 1*! :K''! /,+1&*%/>! 0&12! 12,! &%+&/&*%/!'$-,! &%! 12,! /$',!
(#$%,! $/! 12$1! *7! 12,! $T&$#! UB@^BH! /,+1&*%/F! H2,! 1.'*.)! 0$/! 12,%! &-,%1&7&,-! $%-!
/$'(#,/!1$L,%!7*)!)*.1&%,!($12*#*R&+$#!/1$R&%RF!"--&1&*%$#!/$'(#,/!0,),!$+Y.&),-!7*)!
12,! /1.-DF! 3(! 1*! W! /,+1&*%/!0,),! *P1$&%,->! -,(,%-&%R! *%! 12,! /&_,! *7! 12,! 1.'*.)>!





(*//&P#,>! /2*0&%R! 12,! *)&,%1$1&*%! *7! 12,! 1.'*.)! 0&12&%! 12,! #.%R! $%-! 12,! 1&//.,!
),'*?,-!()&*)! 1*! 12,!/(,+&',%!P,&%R!(#$+,-! &%! 12,!+$//,11,F! E7! 12,! 1.'*.)!/,+1&*%!
-&$',1,)!0$/!R),$1,)!12$%!S+'>!12,!/(,+&',%!0$/!12,%!+.1!$%-!/1*),-!&%!,&12,)!G!*)!





E''.%*2&/1*+2,'&+$#! /1$&%&%R! 0$/! .%-,)1$L,%! ./&%R! $! ?,)D! /,%/&1&?,! #$P,##,-!
(*#D',)! ',12*-! 7*)! 2.'$%! 1&//.,F! H2,! '$1,)&$#/! $%-! ',12*-/! -,/+)&P,-! P,#*0!




































0,),! 12,%! #$P,##,-! 0&12! 12,&)! .%&Y.,! &-,%1&7&,)! ./&%R! ,&12,)! (,%+&#! *)! $! (,)'$%,%1!
'$)L,)F!H2,/,!0,),! 12,%!'*.%1,-!*%1*!'&+)*/+*(,!/#&-,/!$%-!-)&,-! 7*)!:!2*.)!$1!
S[qBF! U,0$T&%R! 0$/! .%-,)1$L,%! PD! (#$+&%R! /#&-,/! &%! TD#,%,! 7*)! S! '&%.1,/F! H2,!
/#&-,/!0,),!),2D-)$1,-!12)*.R2!R)$-,-!$#+*2*#/!5:KKZ>!;KZ!$%-![KZ9!1*!0$1,)!12,D!





H0*! -&/2,/>! ,$+2! +*%1$&%&%R! GKK'#! -&/1&##,-! 0$1,)>! 0,),! (),2,$1,-! 1*! W[dB! &%! $!




1*! 12,! ,%_D',! P$12! 7*)! S!'&%.1,/! 12,%! 0,),! ),'*?,-! $%-! (#$+,-! &%! ).%%&%R! 1$(!
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12,! 1)*.R2>! 02&+2! 0$/! 12,%! (#$+,-! *%! $%! *.1,)! $),$! *7! '&+)*0$?,! 1.)%1$P#,! $%-!
2,$1,-!$1! 7.##! (*0,)! 7*)!V!'&%.1,/F! !H2,! #*/1! 7#.&-!0$/! 12,%! ),(#$+,-!0&12!-&/1&##,-!
0$1,)F!H2&/!()*+,//!*7!2,$1&%R!$1! 7.##!(*0,)! 7*)!V!'&%.1,/!0&12! ),(#$+,',%1!*7! 12,!
#*/1! 7#.&-!0$/!),(,$1,-!10&+,!'*),F!X*##*0&%R!12,!7&%$#!2,$1&%R!$%-!1*((&%R!.(!0&12!
0$1,)>! 12,! 1)*.R2!0&12!/#&-,/>!0$/! #,71! 1*!/1$%-! 7*)!GK!'&%.1,/F!H2,!/#&-,! )$+L!0$/!





I*! (),^1),$1',%1! 0$/! .%-,)1$L,%>! .%#,//! /(,+&',%/! /1$&%,-! (**)#D>! 02,%! KF:Z!
B2D'*1)D(/&%! (),^1),$1',%1! 5$/! (,)! /,+1&*%! GFSFSF:9! 0$/! ./,-! ()&*)! 1*! /1$&%&%R!
7.)12,)!/,+1&*%/!7)*'!12,!/$',!/(,+&',%F!"1!12&/!(*&%1!12,!/#&-,/!0,),!0$/2,-!0,##!
&%!0$1,)!$%-!(,)*T&-$/,!P#*+L!5U$L*BD1*'$1&*%!6GKGW9!0$/!$((#&,-!7*)!S!'&%.1,/F!
H2,! /#&-,/! 0,),! 12,%! 0$/2,-! 0,##! &%! 0$1,)>! )&%/,-! 0&12! HM6! $%-! ()*1,&%! P#*+L!
5U$L*BD1*'$1&*%!bK;K;9!0$/!$((#&,-!7*)!S!'&%.1,/>!0&12!12,!,T+,//!12,%!1&((,-!*77F!
J*./,! $%1&^2.'$%! BUWV! 5mP,%-:K9! $%1&P*-D! 5I*?*+$/1)$! IB]^@%-9>! -&#.1,-! 1*!
:N:KK!&%!$%1&P*-D!-&#.,%1!5U$L*BD1*'$1&*%!6GKGG9>!0$/!$((#&,-!7*)!:!2*.)!$1!)**'!
1,'(,)$1.),F!H2,!/#&-,/!0,),!12,%!)&%/,-!&%!HM6!W!1&',/!*?,)!W!1*!S!'&%.1,/F!U$L*!





12,%! 0$/2,-! 0,##! &%! 0$1,)! $%-! (,)*T&-$/,! P#*+L! 5U$L*BD1*'$1&*%! 6GKGW9! 0$/!
$((#&,-! 7*)!S!'&%.1,/F!X*##*0&%R! 12&/>! 12,!/#&-,/!0,),!0$/2,-!0,##! &%!0$1,)>! )&%/,-!
0&12! HM6! $%-! ()*1,&%! P#*+L! 5U$L*BD1*'$1&*%! bK;K;9! 0$/! $((#&,-! 7*)! S! '&%.1,/>!
12,%!12,!,T+,//!0$/!1&((,-!*77F!aD(*TD()*P,!:J$P:!5VFWF::FW9!5I$1.)$#!82$)'$+&$9>!
-&#.1,-!1*!:N:KK!&%!$%1&P*-D!-&#.,%1!5U$L*BD1*'$1&*%!6GKGG9!0$/!$((#&,-!7*)!:!2*.)!
$1! )**'! 1,'(,)$1.),F! H2,! /#&-,/! 0,),! 12,%! )&%/,-! &%! HM6! W! 1&',/! *?,)! W! 1*! S!






0$/2,-!0,##! &%!0$1,)! $%-!(,)*T&-$/,!P#*+L! 5U$L*BD1*'$1&*%!6GKGW9!0$/!$((#&,-!
7*)!S!'&%.1,/F!X*##*0&%R!12&/!12,!/#&-,/!0,),!0$/2,-!0,##!&%!0$1,)>!)&%/,-!0&12!HM6!
$%-! ()*1,&%! P#*+L! 5U$L*BD1*'$1&*%! bK;K;9! 0$/! $((#&,-! 7*)! S! '&%.1,/>! 12,%! 12,!
,T+,//! 0$/! 1&((,-! *77F! C#.1^:! 568a^V;<9! $%1&P*-D! 5"P+$'! $PVKK<V9>! -&#.1,-! 1*!
:NWKK!&%!$%1&P*-D!-&#.,%1!5U$L*BD1*'$1&*%!6GKGG9>!0$/!$((#&,-!7*)!:!2*.)!$1!)**'!
1,'(,)$1.),F!H2,!/#&-,/!0,),!12,%!)&%/,-!&%!HM6!W!1&',/!*?,)!W!1*!S!'&%.1,/F!U$L*!




"71,)! 12,!-)$&%$R,!*7!,T+,//! 7#.&->!U&$'&%*P,%_$-&%,! 5U"M9!/.P/1)$1,! 5c,+1*)!64^








H2,! /,#,+1,-! 2&/1*#*RD! /#&-,! 0$/! +#,$%,-! *7! -./1! $%-! $%D! ),/&-.$#! .%0$%1,-!
,T1,)%$#! '$)L/>! 12,%! 7&T,-! &%! (*/&1&*%! *%! 12,! '&+)*/+*(,! /1$R,F! "! I&L*%! ,+#&(/,!
H@GKK!'&+)*/+*(,!5VT!*PQ,+1&?,9!$%-!$!tcB!4u^X[S3!+$',)$!5:W=K!T!:KGV!(&T,#9!
0,),!./,-! &%!+*%Q.%+1&*%!0&12! &%^2*./,!'&+)*/+*(,!+*%1)*#!/*710$),! 5v]&/1,)\^!C)$D!
B$%+,)! E%/1&1.1,>! I*)120**->! J&--#,/,T>! 349! 1*! $+Y.&),! -&R&1$#! &'$R,/F! E%!
(),($)$1&*%! 7*)! &'$R,! $+Y.&/&1&*%>! P$+LR)*.%-! +*)),+1&*%/! 0,),! (,)7*)',-! 1*!
+*'(,%/$1,! 7*)! -&/+*#*.)$1&*%! $%-! &##.'&%$1&*%! %*%^.%&7*)'&1&,/e! "! 02&1,! $?,)$R,!
&'$R,! 5`9!0$/!$+Y.&),-! 7)*'!$! +#,$%!$),$!*%! 12,! /#&-,!$-Q$+,%1! 1*! 12,! ),R&*%! *7!
&%1,),/1!5AOE9f!"!P#$+L!$?,)$R,!&'$R,!5M9!0$/!$+Y.&),-!02&#/1!12,!#&R21!/*.)+,!0$/!
*++#.-,-F! H2,! +*)),+1,-! &'$R,! 0$/! 12,%! +),$1,-! 7)*'! 12,! *)&R&%$#! &'$R,! 5E9! PD!
+$#+.#$1&%R!5E^M9N5`^M9F!H2,!#&'&1/!*7!12,!AOE!0,),!12,%!-,7&%,-!./&%R!T!$%-!D!/1$R,!
+**)-&%$1,/!$%-!12,%!12,!7*+$#!(#$%,!0$/!-,7&%,-!PD!12,!./,)!7*+.//&%R!*%!W!(*&%1/!
0&12&%! 12,!AOE! 12$1!0,),!/,#,+1,-!PD!12,!+*'(.1,)F!H2,!/*710$),!0$/!12,%!$P#,! 1*!
1$L,! &%1*! $++*.%1! 12,! /(,+&',%\/!'*.%1&%R! $%R#,! $%-!,%/.),! $##! $+Y.&),-! &'$R,/!
0,),! &%! 7*+./F! H2,! ),R&*%! /+$%! 0$/! 12,%! /1$)1,-e! '.#1&(#,! &'$R,/! 0,),! $+Y.&),-!
/,Y.,%1&$##D! 7*)! 12,! 02*#,! AOE>! 0&12! $! (),-,7&%,-! *?,)#$(! *7! :KZ! P,10,,%! ,$+2!
&'$R,>!12,!'*1*)&/,-!/1$R,!'*?&%R!12,!/(,+&',%!P,10,,%!,$+2!&'$R,!$+Y.&/&1&*%F!
"##!12,!),/.#1$%1!&'$R,/!0,),!/$?,-!.%-,)!12,!),#,?$%1!7&#,%$',!$/!F&+/!7&#,/!5U,$%!
,1! $#F>! :;;K9F! "%! &%^2*./,! /*710$),! ()*R)$'! 5vE'$R,! 61&1+2&%R\! n! C)$D! B$%+,)!
E%/1&1.1,>!I*)120**->!J&--#,/,T9!0$/!12,%!./,-!1*!()*-.+,!$!/&%R#,!&'$R,!7)*'!12,!
'.#1&(#,! $+Y.&),-! &'$R,/>! 0&12! 12,! :KZ! *?,)#$(! ),'*?,-F! H*! ()*-.+,! 12&/! &'$R,!












*%! $! (&T,#^PD^(&T,#! P$/&/>! ,%$P#,-! $%$#D/&/! *7! &''.%*2&/1*+2,'&+$#! /1$&%! +*#*.)!
&%1,%/&1D! 1*! P,! .%-,)1$L,%F! H2&/! $%$#D/&/! 0$/! (,)7*)',-! ./&%R! &%^2*./,! /*710$),!
5vHAEG\! n! C)$D! B$%+,)! E%/1&1.1,>! I*)120**->! J&--#,/,T>! 349F! A,7,),%+,! &%1,%/&1D!
),-^R),,%^P#.,!/(,+1)$#!($11,)%/! 7*)! 12,!P)*0%!*7! 12,!U"M!/1$&%&%R!$%-!12,!P#.,!*7!
12,!2$,'$1*TD#&%!/1$&%&%R!0,),!-,1,)'&%,-!7)*'!12,!/1*),-!F1&7!&'$R,/!PD!$%$#D/&%R!





0$/! .%-,)1$L,%! ./&%R! $! /1$%-$)-! P&%%&%R!',12*->! -.,! 1*! 12,! #$)R,! /&_,! *7! 12,/,!
&'$R,!7&#,/F!"!'$/L!0$/!-)$0%>!-,#&%,$1&%R!12,!AOE!*%!,$+2!/#&-,>!0&12!12,/,!AOE/!
/$?,-!$/!$!P&%$)D!FP'(!5P&1'$(9!7&#,/>!02,),!:!&%-&+$1,/!$!/,#,+1,-!(&T,#!$%-!K!$%!
.%0$%1,-!(&T,#F! v]&%,$)!.%'&T&%R\!0$/! 12,%!*(,%,-! &%! 12,!/*710$),!$%-! 12,!P)*0%!
$%-!P#.,! ),7,),%+,/! 7*)! 12,!/(,+&7&+!/1$&%! #*$-,-F!]&%,$)!.%'&T&%R!0$/! &%&1&$1,-!PD!
+#&+L&%R!*%! vC*\!$%-!12,%!$!/,($)$1,-!),7,),%+,!:!512,!P)*0%!/1$&%&%R!(&T,#/!0&12&%!
12,! '$/L! $),$9! &'$R,! 0$/! ()*-.+,-! $%-! /$?,-! $/! $%! F&+/! 7&#,F! H2&/! &'$R,! 0$/!
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H2,! '.#1&(#,! &'$R,! /1$1&/1&+/! '$+)*! $%$#D/,/! $##! &'$R,/! &%! 12,! -,/&R%$1,-! %,0!
0*)L/($+,! -,1,)'&%&%R! 1*1$#! &%1,%/&1D>! $?,)$R,! &%1,%/&1D>! /1$%-$)-! -,?&$1&*%>!
/1$%-$)-!,))*)>!'*-$#! ?$#.,>!'*-$#! 7),Y.,%+D!$%-!'$/L!$),$F!H2,!-$1$!()*-.+,-!
0$/! $.1*'$1&+$##D! /$?,-! &%! $%!@T+,#! /(),$-/2,,1! 5FT#/9! 7*)'$1F! H2&/! $%$#D/&/!0$/!





/1$&%! 0,),! /,1>! 0&12! J&%&'.'! $1! KFG! $%-! J$T&'.'! $1! :KKKf! 12&/! /+$#,! 0$/! 12,%!
+*(&,-! $%-! $((#&,-! 1*! $##! &'$R,/! &%! 12,! 0*)L/($+,F! H2,!'.#1&(#,! &'$R,! /1$1&/1&+/!
'$+)*! 0$/! 12,%! ).%! $/! P,7*),! 0&12! 12,! v"((#D! '$/L\! /,#,+1,-! P.1! 0&12*.1!
%*)'$#&/$1&*%F!"R$&%!12,!),/.#1$%1!-$1$!0$/!/$?,-!$/!$!FT#/!7&#,F!
!
E%! $--&1&*%! 1*! +$#+.#$1&%R! 12,! &%1,%/&1D! $%-! /.''$)D! /1$1&/1&+/! *7! 12,!
&''.%*2&/1*+2,'&+$#! /1$&%&%R>! 12,!(,)+,%1$R,!*7! 12,! /#&-,! /1$&%&%R!0&12! ,$+2!0$/!
$#/*!,T$'&%,-F! E%&1&$##D! 12,!7)$+1&*%!*7! 12,!'$/L!$),$!5%.'P,)!*7!(&T,#/9!/1$&%,-!PD!
,$+2! &''.%*2&/1*+2,'&+$#! /1$&%! 0$/! -,)&?,-! ./&%R! 12,! 7*##*0&%R! ,Y.$1&*%e! J$/L!
$),$! 5/1$&%,-! (&T,#/9N!J$/L! $),$! 502*#,!AOE9F! H2&/! ,%$P#,-! 12,! +$#+.#$1&*%! *7! 12,!
(,)+,%1$R,!/1$&%&%R!PD!'.#1&(#D&%R!12,!61$&%,-!7)$+1&*%!PD!:KKF!
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2.6  Statistical Analysis 
61$1&/1&+$#! $%$#D/&/! 0$/! (,)7*)',-! ./&%R! J&+)*/*71r! @T+,#! GKKK! 5J&+)*/*71!










O%,! 0$D! "IOc">! 7*##*0,-! PD! H.L,D^4)$',)! '.#1&(#,! +*'($)&/*%/! 1,/1&%R>! $%-!
J$%%^`2&1%,D! 3! 1,/1! 0,),! ./,-! 1*! +*'($),! R)*.(! ',$%/! 7*)! 12,! 1&',/! 1*! 12,!





B*)),#$1&*%! P,10,,%! UB@^BH! ',$/.),',%1/! 586>! Mc! $%-! MX9! $%-!
&''.%*2&/1*+2,'&+$#! ($)$',1,)/! 5(&'*%&-$_*#,! $%-! C#.1^:! ,T(),//&*%9! 0$/!
$//,//,-!PD!6(,$)'$%!)$%L!+*)),#$1&*%F!J$%%^`2&1%,D!3^1,/1!0$/!./,-!1*!$//,//!
$//*+&$1&*%/!P,10,,%!UB@^BH!',$/.),',%1/!*)!&''.%*2&/1*+2,'&+$#!($)$',1,)/!
$%-! +#&%&+*^($12*#*R&+$#! ($)$',1,)/! 52&/1*#*R&+$#! /.P1D(,>! R)$-,>! /1$R,! $%-! %*-$#!
/1$1./9F! E%! *)-,)! 1*! ,?$#.$1,! 12,! ,77,+1/! *7! 1.'*.)! 2,1,)*R,%,&1D! *%! P*12!UB@^BH!











































































































































































































































































































































































































































































































































































































































































































Preclinical evaluation of nitric oxide synthase 
inhibition alone or in combination with radiation 
and vascular disruption. 
!




x! "#! $%&%'()*%!89%&9%'! &9%! -$$)&)#*! #3! 29'#*)2! #'-,! #'! );+;! 45667! %*9-*2%.!
&0(#0'!:'#8&9!$%,-=!)*!2#(>)*-&)#*!8)&9!3'-2&)#*-&%$!'-$)#&9%'-+=;!
x! "#! $%&%'()*%!89%&9%'! &9%! -$$)&)#*! #3! 29'#*)2! #'-,! #'! );+;! 45667! %*9-*2%.!
&0(#0'! :'#8&9! $%,-=! )*! 2#(>)*-&)#*! 8)&9! 8%%1,=! 2#(>'%&-.&-&)*! 7?!
+9#.+9-&%;!
x! "#!$%&%'()*%!89%&9%'! &9%!-$$)&)#*!#3!29'#*)2!#'-,!45667!%*9-*2%.! &0(#0'!
:'#8&9! $%,-=! )*! 2#(>)*-&)#*! 8)&9! $-),=! ,#8! $#.%! 2#(>'%&-.&-&)*! 7?!
+9#.+9-&%;!
x! "#!$%&%'()*%!89%&9%'! &9%!-$$)&)#*!#3!29'#*)2!#'-,!45667!%*9-*2%.! &0(#0'!




3.2  Introduction 
"9).! 29-+&%'! 2#*&-)*.! $%&-),.! #3! +'%2,)*)2-,! %@+%')(%*&./! %@-()*)*:! &9%!
+9-'(-2#1)*%&)2.!-*$!%33%2&.! #*! &0(#0'!:'#8&9!#3! $)33%'%*&! .29%$0,%.!#3! &9%!*#*5
).#3#'(! .+%2)3)2! 6AB! )*9)>)&#'/! 45667;! "9%! (0')*%! (-((-'=! -$%*#2-'2)*#(-!
&0(#0'! (#$%,! C-6"! 8-.! .%,%2&%$! -.! )&! 9-$! >%%*! 0.%$! .022%..30,,=/! )*! .&0$)%.!









>%! 3%-.)>,%! )*! &9%! 2,)*)2-,! .%&&)*:;! 7$$)&)#*-,,=! &9%=! -,,#8%$! 2#(+-').#*! #3! &9%!
+9-'(-2#1)*%&)2.! #3! $)33%'%*&! .29%$0,%.! #3! 45667V! .)*:,%! );+;! $#.%/! 3)E%! $-),=! );+;!
$#.%.!-*$!29'#*)2!#'-,!-$()*).&'-&)#*!)*!&9%!$')*1)*:!8-&%';!W.)*:!-!&0(#0'!:'#8&9!
$%,-=! -..-=/! %@+%')(%*&.! 8%'%! 0*$%'&-1%*! &#! -..%..! &9%! )(+-2&! #3! $)33%'%*&!





3.3! ! Methods 
X;X;S!! "0(#0'.!-*$!"'%-&(%*&.!
"9).!8#'1!8-.!0*$%'&-1%*!0.)*:! &9%!C-6"! &0(#0'!(#$%,! H-.!+%'!.%2&)#*!J;S;S;SQ;!




"9%! +9-'(-2#1)*%&)2.! #3! &9'%%! $)33%'%*&! 45667! .29%$0,%.! 8%'%! -*-,=.%$/! -.! +%'!
.%2&)#*.!J;S;<;!Y#'!F'#0+!S/!-!.)*:,%! )+!$#.%!#3!45667/!SK(:Z!1:/!8-.!:)E%*!8)&9!
.-(+,)*:!#*!$-=!S!-&!SK/!JK/!XK/!?K/![K/!\K/!SJK()*.;!F'#0+!J!'%2%)E%$! 3)E%!$-),=!
$#.%.! #3! )+! 45667/! SK(:Z! 1:/! 8)&9! .-(+,)*:! #*! $-=! <! -&! SK/! JK/! XK/! ?K/! [K/! \K/!
SJK()*.;! 45667/!S(:Z(,/!8-.!-$()*).&%'%$! 2#*&)*0#0.,=! )*! &9%!$')*1)*:!8-&%'! 3#'!
:'#0+! X/! 8)&9! .-(+,)*:! -&! SK-(! #*! $-=.! J/! </! ]/! \! -*$! ?+(! #*! $-=.! J/! </! ];! G*!
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3.4   Results 
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3.4.2  Tumour Growth Delay Studies 
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3.5  Discussion 
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3.6  Conclusion 
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! 45667!JT8! 45667!<T8! 45667!A!
C7?D!HSKKQ! @! @! @!
C7?D!H<KQ!! 5! 5! @!
O"! @! @! @!
O"!k!C7?D!HSKKQ! 5! 5! @!
O"!k!C7?D!H<KQ! 5! 5! @!
!
Table 3.1 
Combinations of treatments studied: L-NNA 2qw - 10mg/ kg ip on days 3, 4, 10, and 
11; L-NNA 5qw  - 10mg/ kg ip on days 0- 4 and 7- 11; L-NNA O- 1mg/ ml 
continuously in drinking water; CA4P (100)- 100mg/ kg ip on days 4 and 11; 
CA4P(50)- 50mg/ kg ip on days 0-4 and 7- 11; RT- radiotherapy, 40 Gray in 8 daily 
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2#*2%*&'-&)#*! #3! S! (:Z! (,! 2#*&)*0#0.,=^! L-NNA O! -*$! L-NNA 5qw! .):*)3)2-*&,=!
%*9-*2)*:! &0(#0'! :'#8&9! $%,-=! 2#(+-'%$! &#! 2#*&'#,.;!i%%1,= CA4P (100) -,#*%/!



































C-6"!(0')*%! &0(#0'.;!D#)*&.! '%+'%.%*&!(%-*.!n!S!BR`! 3#'!<5[!-*)(-,.;!i%%1,= 
CA4P (100) -,#*%/!SKK(:Z!1:! );+;!#*2%!+%'!8%%1! H#*!$-=!?!-*$! '%+%-&%$!#*!$-=!
SSQ/! !-*$! )*!2#(>)*-&)#*!8)&9!%)&9%'!L-NNA 2qw:!SK(:Z!1:! );+;! &8)2%!+%'!8%%1!H#*!
$-=.!X/!?/!SK!-*$!SSQ/!L-NNA 5qw: SK(:Z!1:!);+;!3)E%!&)(%.!+%'!8%%1!H#*!$-=.!K!&#!?!
-*$!U!&#!SSQ!-*$!L-NNA O:!#'-,,=!)*!&9%!$')*1)*:!8-&%'!-&!-!2#*2%*&'-&)#*!#3!S!(:Z!(,!
2#*&)*0#0.,=;! &9%! 2#(>)*-&)#*.! #3! CA4P (100) 8)&9! L-NNA O! -*$! L-NNA 5qw!
.):*)3)2-*&,=!%*9-*2)*:!&0(#0'!:'#8&9!$%,-=!2#(+-'%$!&#!CA4P (100)!-,#*%;!
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R33%2&! #3! $-),=! C7?D! )*! 2#(>)*-&)#*! 8)&9! #'-,! 45667! .29%$0,%! #*! &9%! :'#8&9! #3!
C-6"! (0')*%! &0(#0'.;! D#)*&.! '%+'%.%*&! (%-*.! n! S! BR`! 3#'! <5[! -*)(-,.;! M-),=!
CA4P (50),!<K(:Z!1:!);+;!3)E%!&)(%.!+%'!8%%1!H#*!$-=.!K5?!-*$!U5SSQ/!-,#*%!-*$!)*!
2#(>)*-&)#*!8)&9!L-NNA O,!#'-,,=! )*!&9%!$')*1)*:!8-&%'!-&!-!2#*2%*&'-&)#*!#3!S!(:Z!
(,!2#*&)*0#0.,=^!&9%!2#(>)*-&)#*!#3!CA4P (50)!-*$!L-NNA O .):*)3)2-*&,=!%*9-*2)*:!
&0(#0'!:'#8&9!$%,-=!2#(+-'%$!&# CA4P (50) -,#*%;!
!
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);+;! 3)E%! &)(%.!+%'!8%%1! H#*! $-=.! K! &#! ?! -*$! U! &#! SSQ! -*$!L-NNA O:! #'-,,=! )*! &9%!
$')*1)*:! 8-&%'! -&! -! 2#*2%*&'-&)#*! #3! S! (:Z! (,! 2#*&)*0#0.,=^! *#! %*9-*2%(%*&! #3!
&0(#0'!:'#8&9!$%,-=!.%%*!8)&9!2#(>)*-&)#*!&'%-&(%*&.;!
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R33%2&! #3! #'-,! 45667! .29%$0,%! #*! &9%! :'#8&9! #3! C-6"! (0')*%! &0(#0'.! )*!
2#(>)*-&)#*! 8)&9! 3'-2&)#*-&%$! '-$)#&9%'-+=! -*$! 8%%1,=! C7?D;! D#)*&.! '%+'%.%*&!
(%-*.! n! S! BR`! 3#'! <5[! -*)(-,.;! RT/! ?KF=! )*! ]! 3'-2&)#*.! #E%'! J! 8%%1./ )*!
2#(>)*-&)#*!8)&9!L-NNA O,!#'-,,=! )*!&9%!$')*1)*:!8-&%'!-&!-!2#*2%*&'-&)#*!#3!S!(:Z!
(,! 2#*&)*0#0.,=^! #'! CA4P (100)/! SKK(:Z! 1:! );+;! #*2%! +%'! 8%%1! H#*! $-=! ?! -*$!
'%+%-&%$! #*! $-=! SSQ; RT! -*$! CA4P (100)! .):*)3)2-*&,=! %*9-*2%$! &0(#0'! :'#8&9!
$%,-=!2#(+-'%$!&#!RT!-,#*%;!
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Preclinical evaluation of EGFR inhibition in 
combination with radiation and vascular 
disruption. 
!
4.1  Aims  
x! "#! $%&%'()*%! +,%&,%'! &,%! -$$)&)#*! #.! /#(0'%&-1&-&)*234! 5,#15,-&%! &#!
/%&67)(-0! 8%-$1! &#! %*,-*/%$! 9'#+&,! $%8-:! +,%*! 61%$! &#! &'%-&! )(58-*&%$!
,6(-*!1;6-(#61!/%88!7%*#9'-.&<!=->6<!&6(#6'1!#*!.%(-8%!*6$%!()/%?!
x! "#! $%&%'()*%! +,%&,%'! &,%! -$$)&)#*! #.! /#(0'%&-1&-&)*234! 5,#15,-&%! &#!
/%&67)(-0!)*!/#(0)*-&)#*!+)&,!'-$)#&,%'-5:!8%-$1!&#!%*,-*/%$!9'#+&,!$%8-:!
+,%*! 61%$! &#! &'%-&! )(58-*&%$! ,6(-*! 1;6-(#61! /%88! 7%*#9'-.&<! =->6<!
&6(#6'1!#*!.%(-8%!*6$%!()/%?!
x! "#! $%&%'()*%! +,%&,%'! '-$)#&,%'-5:! .'-/&)#*! 1)@%! ,-1! -*! %..%/&! #*! &,%!





4.2  Introduction 





5'%/8)*)/-8! 1&6$)%1<! +,%'%! &,%! -$$)&)#*! #.! /%&67)(-0! &#! .'-/&)#*-&%$! '-$)#&,%'-5:!
$%/'%-1%$! '%5#568-&)#*! -*$! )*/'%-1%$! '%#7:9%*-&)#*! '%168&)*9! )*! )(5'#D%$! 8#/-8!
&6(#6'!/#*&'#8!IJ'-61%!%&!-8?<!KLLMN?!
!
31! /-*/%'! &'%-&(%*&1! %D#8D%! &#+-'$1! -! (68&)2&-'9%&%$! -55'#-/,<! $)..%'%*&!
/#(0)*-&)#*1!#.!&,%'-5)%1!-'%!0%)*9!%7-()*%$?!EF=G!#D%'%75'%11)#*!)*!OPHBB!)1!
-11#/)-&%$!+)&,!,)9,! 8%D%81!#.!QEF=23!-*$!QEF=2B<!-*$!-81#!+)&,!5##'!5'#9*#1)1!





,%-$!-*$!*%/A!/-*/%'!7%*#9'-.&1<! '%168&%$! )*!0#&,!%*,-*/%$! &6(#6'!9'#+&,!$%8-:!
-*$!%*,-*/%$!D-1/68-'!%..%/&!I]#@%/!%&!-8?<!KLL\N?!F%.)&)*)0!,-1!-81#!0%%*!/#(0)*%$!
+)&,![>\TK\!-*$!.'-/&)#*-&%$!'-$)#&,%'-5:!)*!-!*#*!1(-88!/%88!86*9!/-*/%'!IPHBUBN!
7%*#9'-.&!(#$%8<!+)&,! &,)1! &')58%!/#(0)*-&)#*!1)9*).)/-*&8:! )*/'%-1)*9! &6(#6'!9'#+&,!
$%8-:!/#(5-'%$!&#!'-$)#&,%'-5:!-*$!%)&,%'!9%.)&)*)0!#'![>\TK\!-8#*%?!IG-0%*!%&!-8?<!
KLL4N?!^1)*9!-!&6(#6'!9'#+&,!$%8-:!-11-:<!%75%')(%*&1!+%'%!6*$%'&-A%*!&#!-11%11!
&,%! )(5-/&! #.! /%&67)(-0! -*$! %1&-08)1,! +,%&,%'! )&1! /#(0)*-&)#*! +)&,! .'-/&)#*-&%$!
'-$)#&,%'-5:!-*$!B34C!/#68$!%*,-*/%!&,%!-*&)2&6(#6'!%..%/&1!#.!&,%1%!&'%-&(%*&1?!





4.3! ! Methods 
4?_?T!! "6(#6'1!-*$!"'%-&(%*&1!





388! &'%-&(%*&!1/,%$68%1!+%'%!-$()*)1&%'%$!#D%'!-!/#(5-'-08%! &+#!+%%A!5%')#$! &#!
%*16'%! 6*).#'()&:?! B34C! ITLL(9`! A9N! )?5?! #*/%! 5%'! +%%A! I#*! &,%! M&,! $-:! #.! %-/,!
+%%AN!+-1!1&6$)%$!-8#*%<!)*!/#(0)*-&)#*!+)&,!BKKM!IT(9`!(#61%N!)?5?!%D%':!_!$-:1!
.#'! 4! $#1%1! )*! &#&-8<! )*! /#(0)*-&)#*! +)&,! '-$)#&,%'-5:! I1/,%$68%! -1! $%1/')0%$!
5'%D)#618:N! 5861! -88! 5#11)08%! /#(0)*-&)#*1! #.! &,%1%! &,'%%! &'%-&(%*&1?! a,%*!
/%&67)(-0!+-1!9)D%*! )*!/#(0)*-&)#*!+)&,! '-$)#&,%'-5:<! &,%! .)'1&!$#1%!+-1!9)D%*!-&!
8%-1&! \! ,#6'1!5')#'! &#! &,%! /#((%*/%(%*&! #.! '-$)#&,%'-5:?!B34C<!+,%*! /#(0)*%$!









5#)*&! +%'%! 61%$! .#'! 0#&,! 9'#651?! F'#65! T! '%/%)D%$! -! 1)*98%! )?5?! $#1%! #.! B34C<!
TLL(9`!A9?!F'#65!K!'%/%)D%$!)?5?!/%&67)(-0<!T(9!)*!L?M(8!#*!$-:!T!&,%*!-9-)*!#*!
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$%8-:1! -*$! &,%! &)(%! &#! $%D%8#5(%*&! #.! 8:(5,! *#$%!(%&-1&-1%1<! 5'#$6/%$! 0:! &,%!
D-')#61! &'%-&(%*&! 9'#651<! -'%! $%1/')0%$! )*! 1%/&)#*! K?\?T! -*$! 1%/&)#*! K?\?K!
'%15%/&)D%8:?!!
 
4.4   Results 
4?4?T!! "6(#6'!F'#+&,!>%8-:!H&6$)%1 
4?4?T?T! ! B34C!-*$!/%&67)(-0  











K\?_! $-:1<! -! &6(#6'! 9'#+&,! $%8-:! #.! TL?M! $-:1! /#(5-'%$! &#! &,-&! .#'! /#*&'#81!
I5cL?LLLTN?! ",%! /6'D%1! .#'! -88! #.! &,%! 9'#651! '%/%)D)*9! '-$)#&,%'-5:! -&! KF:! 5%'!
.'-/&)#*<! &#!-!&#&-8!$#1%!#.!T\F:<!$%8)D%'%$!#D%'!K!+%%A1<!-'%!1,#+*!)*!=)96'%!4?K?!
 146
",%!9'%-&%1&! &6(#6'!9'#+&,!$%8-:<!-&! &,)1!$#1%!5%'! .'-/&)#*<!+-1!5'#$6/%$!0:! &,%!
/#(0)*-&)#*!#.!'-$)#&,%'-5:<!/%&67)(-0!-*$!B34C?!",)1!&')58%!/#(0)*-&)#*!'%168&%$!
-! &)(%! &#! &6(#6'! '%9'#+&,! I&#! &+)/%! #')9)*-8! D#86(%N! #.! _K?K! $-:1<! +)&,! &6(#6'!
9'#+&,!$%8-:1!#.!M?Y!$-:1!/#(5-'%$! &#! '-$)#&,%'-5:!-8#*%<!4?V!$-:1!/#(5-'%$! &#!
'-$)#&,%'-5:! /#(0)*%$! +)&,! /%&67)(-0! -*$! _?Z! $-:1! /#(5-'%$! &#! '-$)#&,%'-5:!






&,%! 9'#65! '%/%)D)*9! /%&67)(-0! -*$! B34C<! )*! /#(0)*-&)#*! +)&,! '-$)#&,%'-5:! -&! -!
$#1%!5%'! .'-/&)#*!#.!K?MF:<!$%(#*1&'-&%$! &,%!9'%-&%1&! &)(%! &#! &6(#6'! '%9'#+&,! I&#!
&+)/%!#')9)*-8! D#86(%N!#.! M_?_!$-:1?!",)1! /#(0)*-&)#*!5'#$6/%$! 1)9*).)/-*&! &6(#6'!
9'#+&,! $%8-:1! -&! &,)1! $#1%! 5%'! .'-/&)#*d! T4?Z! $-:1! I5eL?LTY_N! /#(5-'%$! &#!
'-$)#&,%'-5:!-8#*%<!-*$!T4?Y!$-:1!I5eL?LKY_N!/#(5-'%$!&#!'-$)#&,%'-5:!/#(0)*%$!
+)&,!B34C?!",%1%!/-8/68-&)#*1!+%'%!6*$%'&-A%*!%7/86$)*9!$-&-!.'#(!T!(#61%!)*!&,%!
'-$)#&,%'-5:! -8#*%! 9'#65! -*$! .'#(! K! ()/%! )*! &,%! '-$)#&,%'-5:! -*$! B34C! 9'#65?!
",%1%!+%'%!%7/86$%$<! -1! &,%! &6(#6'1!$)$!*#&! '%-/,!KLLf!#.! &,%!#')9)*-8! D#86(%<!
$6%! &#! &,%!$%D%8#5(%*&!#.! 8-'9%! 8:(5,!*#$%!(%&-1&-1%1! '%;6)')*9! &,%!()/%! &#!0%!
1-/').)/%$?!",%!9'#65!1)@%1!-1!-!'%168&!+%'%!4!()/%!-*$!_!()/%!'%15%/&)D%8:?!!
!
a)&,! %7&'-5#8-&)#*1! .#'! &,%! &6(#6'! 9'#+&,! /6'D%1! I+)&,! 0%&+%%*!L?_! -*$!L?M! $-:1!
0%:#*$! &,%! .)*-8! $-&-! 5#)*&N! .#'! K! ()/%! )*! &,%! '-$)#&,%'-5:! /#(0)*%$! +)&,! B34C!
9'#65<!&,)1!%*-08%$!$-&-!.'#(!-88!M!()/%!)*!&,)1!/#,#'&!&#!0%!61%$!)*!&,%!/#(5-')1#*?!
^1)*9!&,)1!%7&'-5#8-&%$!$-&-!&,%!&6(#6'!9'#+&,!$%8-:1!5'#$6/%$!0:!&,%!/#(0)*-&)#*!
#.! /%&67)(-0<!B34C!-*$! '-$)#&,%'-5:! '%(-)*%$! 1)9*).)/-*&d! T4?Y! $-:1! I5eL?LLMVN<!
/#(5-'%$! +)&,! '-$)#&,%'-5:! /#(0)*%$! +)&,! B34C<! -*$! T4?Z! $-:1! I5eL?LTLTN<!
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/#(5-'%$! +)&,! '-$)#&,%'-5:! -8#*%?! ",%! (-g#'! $)..%'%*/%! '%168&)*9! .'#(! &,%1%!
%7&'-5#8-&)#*1!+%'%!&,-&!'-$)#&,%'-5:!/#(0)*%$!+)&,!/%&67)(-0!-81#!,-$!1)9*).)/-*&!





.'-/&)#*?! ",)1! +-1! *#&! 5#11)08%! .#'! &,%! 9'#651! '%/%)D)*9! '-$)#&,%'-5:! -&! KF:! 5%'!
.'-/&)#*!-*$!&,#1%!9'#651!*#&!'%/%)D)*9!'-$)#&,%'-5:<!$6%!&#! )*16..)/)%*&!(-9*)&6$%!
#.! %..%/&! #*! &6(#6'! 9'#+&,?! ^1)*9! &,)1! -8&%'*-&)D%! %*$5#)*&! #.! &)(%! &#! &6(#6'!
'%9'#+&,!&#!#')9)*-8!D#86(%<!/%&67)(-0!/#(0)*%$!+)&,!B34C!-*$!'-$)#&,%'-5:!+-1!
&,%! #*8:! &'%-&(%*&! /#,#'&! &#! $%(#*1&'-&%! 1)9*).)/-*&! &6(#6'! 9'#+&,! $%8-:1<!
/#(5-'%$!&#!'-$)#&,%'-5:!/#(0)*%$!+)&,!B34C<!-*$!'-$)#&,%'-5:!-8#*%<!TK?Z!$-:1!
I5eL?LT\TN! -*$! T_?Y! $-:1! I5eL?LLV_N! '%15%/&)D%8:?! P#! 1)9*).)/-*&! $)..%'%*/%! +-1!
#01%'D%$! 0%&+%%*! '-$)#&,%'-5:! /#(0)*%$! +)&,! /%&67)(-0! -*$! '-$)#&,%'-5:!
/#(0)*%$! +)&,! /%&67)(-0! -*$! B34C<! .#'! %)&,%'! &,%! &)(%! .#'! &6(#6'! '%9'#+&,! &#!
#')9)*-8!#'!&+)/%!#')9)*-8!D#86(%<!%D%*!+,%*!%7&'-5#8-&%$!$-&-!+-1!)*/86$%$?!
!
",%! /6'D%1! .#'! -88! &,%! 9'#651! '%/%)D)*9! '-$)#&,%'-5:! -&! _F:!5%'! .'-/&)#*! &#! -! &#&-8!
$#1%!#.!K4F:<!$%8)D%'%$!#D%'!K!+%%A1<!-'%!1,#+*!)*!=)96'%!4?4?!=#'!&,)1!$#1%!8%D%8!
#.!'-$)#&,%'-5:!-8#*%<!#*8:!#*%!&6(#6'!'%9'%+!&#!&+)/%!)&1!#')9)*-8!D#86(%<!)*!-!&)(%!
#.!M_?Y!$-:1?!",%!#&,%'!()/%! )*! &,%! '-$)#&,%'-5:!-8#*%!9'#65!,-$! &#!0%!1-/').)/%$!
5')#'! &#! &,%)'! 5')(-':! &6(#6'! '%9'#+)*9<! $6%! &#! &,%! $%D%8#5(%*&! #.! 8:(5,! *#$%!
(%&-1&-1%1<!+,)/,!5'%D%*&%$!D-8)$!1&-&)1&)/-8!/#(5-')1#*!0%&+%%*!&,%!'-$)#&,%'-5:!
-8#*%!9'#65!-*$!&,%!#&,%'!&'%-&(%*&!9'#651<!-&!&,)1!&)(%!5#)*&?!",%!'%(-)*$%'!#.!&,%!
9'#651! ,-$! _! %D-86-08%! ()/%<! +)&,! &,%! /#(0)*-&)#*! #.! /%&67)(-0<! B34C! -*$!








&6(#6'! '%9'#+&,! &#! #')9)*-8! D#86(%?!a)&,#6&! -*:! %7&'-5#8-&)#*<! &,)1! )*/'%-1%$! &,%!
*6(0%'1! #.! ()/%! 5%'! 9'#65! +,%'%! &,%! $-&-! /#68$! 0%! )*/86$%$d! 4! ()/%! )*! &,%!




+)&,! /%&67)(-0! -*$! B34C?! ",)1! 5'#$6/%$! &6(#6'! 9'#+&,! $%8-:1! #.! 4M?_! $-:1!




/%&67)(-0!-*$!B34C<! *%D%'! '%9'%+! &,'#69,#6&! &,%! 1&6$:! 5%')#$<! 65! &#! T_Z!$-:1?!
",%! '%(-)*)*9! 1(-88! 1A)*! *#$68%! +-1! '%1%/&%$! -&! &,%! /#*/861)#*! #.! &,%! 1&6$:<!














-! &#&-8!$#1%!#.!T\F:!#D%'!K!+%%A1<! &,%!(%-*! &)(%! &#!$%D%8#5(%*&!#.! 8:(5,!*#$%!
(%&-1&-1%1<! #'! %*$! #.! %75%')(%*&! ).! *#! (%&-1&-1%1! +%'%! 1%%*<! +-1! 1)9*).)/-*&8:!
8#*9%'!0:!TV!$-:1<!&,-*!1%%*!+)&,!&,%!'-$)#&,%'-5:!/#(0)*%$!+)&,!B34C!/#,#'&<!-*$!





'-$)#&,%'-5:! /#(0)*%$! +)&,! /%&67)(-0! -*$! B34C! #'! '-$)#&,%'-5:! /#(0)*%$! +)&,!
/%&67)(-0! -8#*%<! -*$! -81#! 0%&+%%*! &,%! 9'#651! '%/%)D)*9! '-$)#&,%'-5:! /#(0)*%$!
+)&,!B34C!#'!'-$)#&,%'-5:!-8#*%?!!
!





K! +%%A1<! &,%! #*8:! $)..%'%*/%! &,-&! +-1! 1)9*).)/-*&! +-1! 0%&+%%*! &,%! '-$)#&,%'-5:!
/#(0)*%$! +)&,! /%&67)(-0! -*$! B34C! -*$! &,%! 9'#65! '%/%)D)*9! '-$)#&,%'-5:! -8#*%<!
5'#$6/)*9!-*!)*/'%-1%!)*!&,%!(%-*!&)(%!&#!$%D%8#5(%*&!#.!8:(5,!*#$%!(%&-1&-1%1!
#.!M_?V!$-:1!I5eL?L44ZN?!",%!*%7&!9'%-&%1&!(%-*!)*/'%-1%!#.!_Z!$-:1!I'-$)#&,%'-5:!




=#'! &,%! /#,#'&! '%/%)D)*9! KF:! 5%'! .'-/&)#*<! #*8:! #*%! (#61%! )*! &,%! '-$)#&,%'-5:!
/#(0)*%$!+)&,!/%&67)(-0!/#,#'&!$%D%8#5%$!8:(5,!*#$%!(%&-1&-1%1<!-8&,#69,!)*!&,%!
9'#65!'%/%)D)*9!&,%!1-(%!/#(0)*-&)#*!&'%-&(%*&<!-&!K?MF:!5%'!.'-/&)#*<!*#*%!#.!&,%!
()/%! $%D%8#5%$! 8:(5,! *#$%! (%&-1&-1%1?! ",)1! )1! )*! /#*&'-1&! &#! &,%! '-$)#&,%'-5:!
/#(0)*%$!+)&,!B34C!9'#651!+,%'%!M!#6&!#.!M!-*$!4!#6&!#.!M!$%D%8#5%$!8:(5,!*#$%!
(%&-1&-1%1<! -&! KF:! 5%'! .'-/&)#*! -*$! K?MF:! 5%'! .'-/&)#*! '%15%/&)D%8:?! a,%*! &,%!
9'#651! +%'%! /#(0)*%$! .#'! %-/,! $#1%! 5%'! .'-/&)#*<! )*&#! &,#1%! &,-&! '%/%)D%$!
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Figure 4.2  
E..%/&! #.! .'-/&)#*-&%$! '-$)#&,%'-5:! T\!F'-:! )*! V! .'-/&)#*1! IK!F'-:! 5%'! .'-/&)#*N<! 4!
.'-/&)#*1! 5%'!+%%A!+)&,! -! _! $-:! &'%-&(%*&! 9-5! #*! 9'#+&,! #.! =->6! &6(#6'1!+,%*!
-$()*)1&%'%$!%)&,%'!-8#*%<!5861!B34C!TLL(9`A9!)?5?!+%%A8:!#'!/%&67)(-0!IB%&N!T(9!
































Figure 4.3  
E..%/&!#.! .'-/&)#*-&%$! '-$)#&,%'-5:!KL!F'-:! )*!V! .'-/&)#*1! IK?M!F'-:!5%'! .'-/&)#*N<!4!
.'-/&)#*1! 5%'!+%%A!+)&,! -! _! $-:! &'%-&(%*&! 9-5! #*! 9'#+&,! #.! =->6! &6(#6'1!+,%*!
-$()*)1&%'%$!%)&,%'!-8#*%<!5861!B34C!TLL(9`A9!)?5?!+%%A8:!#'!/%&67)(-0!IB%&N!T(9!































Figure 4.4  
E..%/&! #.! .'-/&)#*-&%$! '-$)#&,%'-5:! K4!F'-:! )*! V! .'-/&)#*1! I_!F'-:! 5%'! .'-/&)#*N<! 4!
.'-/&)#*1! 5%'!+%%A!+)&,! -! _! $-:! &'%-&(%*&! 9-5! #*! 9'#+&,! #.! =->6! &6(#6'1!+,%*!
-$()*)1&%'%$!%)&,%'!-8#*%<!5861!B34C!TLL(9`A9!)?5?!+%%A8:!#'!/%&67)(-0!IB%&N!T(9!


































Figure 4.5  





























Figure 4.6  






Pathophysiological correlates of volumetric 
DCE-CT in resected lung cancers. 
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5.1  Aims  
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5.5  Discussion  
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5.6  Conclusion 
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!! F*2#! E)1&;R! 98V_!
gH! ȡk;OB_dU! p=0.004* ȡkOBNNU! p=0.194 ȡkOBRd[! p=0.274 
F@! ȡkOBN[d! p=0.117 ȡk;OB_SY p=0.002* ȡk;OBOVR p=0.856 
gD! ȡk;OBOUU! p=0.881 ȡkOBRVV! p=0.683 ȡkOBNSR! p=0.358 
@GH2'>! ȡk;OBNRN! p=0.235 ȡkOBV_d! p=0.041* ȡk;OBVVR p=0.049* 
s%*6.*=*3'.&!'&!Um!)$0$)! ! ! ! ! !
 
Table 5.2 
@/$'-2'.! -'.K! 3#--$)'&*#.%! #=! 2$'.! 89:;9"! 4$-*0$4! ()##4! 0#)12$! 7gH<J!
/$-2$'(*)*&5! %1-='3$! '-$'! /-#413&! 7F@<J! ()##4! =)#,! 7gD<! '.4! 2'>*212! %&'.4'-4!
1/&'K$! 0')1$! 7@GH2'><! ,*&+! &+$! =-'3&*#.! %&'*.$4! =#-! V! 4*==$-$.&!






















































































































9#--$)'&*#.! ($&,$$.! 2'>*212! %&'.4'-4! 1/&'K$! 0')1$! 7@GH2'><! '.4! &+$! 2$'.!
89:;9"! 4$-*0$4! /'-'2$&$-%C! A! ()##4! =)#,! 7gD<J! B! ()##4! 0#)12$! 7gH<! '.4! C 
/$-2$'(*)*&5!%1-='3$!'-$'!/-#413&!7F@<B!
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!! gH! F@! gD!
gH! ;! ;! ȡkOBNRd! p=0.454 ȡkOBRNY! p=0.700 
F@! ȡkOBNRd! p=0.454 ;! ;! ȡk;OBOR_! p=0.974 
gD! ȡkOBRNY! p=0.700 ȡk;OBOR_! p=0.974 ;! ;!
@GH2'>! ȡk;OBOVV! p=0.916 ȡk;OBUVd! p=0.050* ȡk;OBRdS! p=0.558 
s%*6.*=*3'.&!'&!Um!)$0$)! ! ! ! ! !
!
Table 5.3 




!! gD! gH! F@! @GH2'>!
Histological subtype ! ! ! !
Q4$.#3'-3*.#2'! _[B[!7RUBS< UBY!7NB_< 17.0 (5.3) 12.2 (3.7) 
@\1'2#1%!3$))! _RBO!7dBN<! [BS!7VBY< 11.2 (1.9) 21.7 (11.6) 
! ! ! ! !
Differentiation ! ! ! !
Z#4$-'&$! _SB_!7RUBS< YBY!7VBS< R_BO!7VBS< RSBR!7RVBV<!
F##-! _RBY!7RRBV< [B_!7NB_< RVBV!7YBO< RUBY!7NB[<!
! ! ! ! !
Pathological stage ! ! ! !
I! 34.4 (3.9) YBO!7NB_< RYBV!7UBU< RVBY!7UB_<!
IIeIII! 51.0 (13.7) [B_!7VB[< RNBN!7VB[< RSBd!7RRBY<!
! ! ! ! !
Pathological nodes ! ! ! !
?O! 35.4 (4.0) YB[!7NBd< RUBd!7UBR< RYBO!7[BY<!
?ReN! 52.7 (13.9) [BR!7VB[< RNBR!7_BO< RdBd!7RNBO<!
!
Table 5.4 
Z$'.! 7%&'.4'-4! 4$0*'&*#.<! 89:;9"! '.4! D8E;F:"! /'-'2$&$-%! '33#-4*.6! &#! &+$!
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Tumour vascular effects of combined vascular 
disruption and radiation in advanced NSCLC 
 
6.1  Aims 
x To determine the reproducibility and repeatability of the volumetric DCE-CT 
technique in assessing whole tumour vascular changes in advanced NSCLC. 
x To determine tumour vascular effects of high dose palliative radiotherapy in 
combination with twice weekly combretastatin A-4 phosphate in advanced 
NSCLC, using volumetric DCE- CT.  
 
6.2  Introduction 
In this chapter, clinical experiments using DCE-CT assessment of the tumour 
vascular changes in patients receiving the VDA CA4P, in addition to radiotherapy, 
for advanced NSCLC are described.  
 
Around 65% of cases of NSCLC present with advanced disease, either Stage IIIB or 
IV. Only 15 to 25% of cases are deemed to be potentially curable by surgical 
resection or radical radiotherapy (Lester et al., 2006). For the remainder of cases 
non-curative treatments and supportive care are the available treatment options, 
with radiotherapy commonly used as a palliative treatment. It was estimated in 1993 
that in the UK 20-30% of cases of NSCLC received palliative radiotherapy (Maher et 
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al., 1993). Many different palliative radiotherapy doses and fractionations are 
currently in clinical use. A high dose palliative lung radiotherapy fractionation, 
delivering 27Gy in 6# over 3 weeks, has been developed at Mount Vernon Hospital, 
Middlesex, UK. In a retrospective study it was shown to have achieved symptomatic 
improvement in 48% of those treated; median survival was 8 months, 1 year overall 
survival was 27% and no grade 3 or 4 toxicities were observed (Corner et al., 2007). 
This radiotherapy fractionation was selected for use in this study as it lends itself to 
the planned escalation of CA4P dose intensity, from single dose up to twice weekly 
administration for the duration of the radiotherapy treatment.  
 
It is well documented that timing, sequence and schedule are of particular 
importance when combining vascular directed therapies with radiotherapy. In 
preclinical studies, the administration of CA4P after or simultaneously with 
radiotherapy has been shown to improve tumour control, but when given prior to 
radiotherapy this beneficial effect was lost (Murata et al. 2001a). A twice weekly 
fractionation offers a minimum 72 hour recovery period after each dose of CA4P, 
therefore avoiding this potential negative effect, by allowing tumour cell 
reoxygenation following the acute CA4P-induced vascular shutdown. Volumetric 
DCE-CT has been used for all 3 NSCLC treatment cohorts in this phase IB study, to 
facilitate comparison of the whole tumour vascular effects, resulting from twice 
weekly CA4P scheduling with the weekly and single dose scheduling from the 
previous 2 cohorts. 
 
6.3  Methods 
6.3.1  Patient selection and recruitment 
All patients were recruited as part of a “Phase 1b trial of CA4P (combretastatin A-4 
phosphate) in combination with radiotherapy in patients with advanced cancer of the 
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lung, head & neck or prostate: CA4P protocol number UKR104”; the full inclusion 
and exclusion criteria of which are shown in Appendix B. Trial recruitment 
commenced in January 2003 following ethical and MHRA approval. Explicit approval 
for the exposure of patients to radiation for research purposes was granted, as 
required by the IR(ME)R (The Ionising Radiation (Medical Exposure) Regulations 
2000) legislation. Each patient gave written informed consent, prior to undergoing 
screening to determine suitability for participation in this study.  
 
The analysis of one cohort of the UKR-104 trial (cohorts 7) is reported in this 
chapter, the treatment scheduling of which is shown in Table 2.1. Patients with 
histologically proven advanced NSCLC (Cohort 7) deemed unsuitable for radical 
treatment, were prospectively recruited. Having fulfilled the criteria for inclusion in 
the study, patients proceeded to receive high dose hypofractionated palliative lung 
radiotherapy, 27Gy in six fractions over 3 weeks (as per section 2.2.1.1). This was 
delivered in combination with CA4P (as per section 2.2.2), 50mg/m2 i.v., 
administered after every fraction of radiotherapy. Each patient was scheduled to 
receive a total of 6 doses of CA4P, the final dose level of a dose escalation study. 
Comparative analysis between the results from cohort 7 and the previously reported 
NSCLC cohorts 1 and 2 was undertaken. The first cohort (cohort 1) had received a 
single dose of CA4P, at a dose of 50mg/m2 i.v. administered following the second 
fraction of radiotherapy only and cohort 2 had received weekly CA4P, 50mg/m2 i.v. 
given after the second, fourth and sixth fractions of radiotherapy. Data from a further 
NSCLC radiotherapy alone cohort were also included when examining the impact of 
changes in technique reproducibility. 
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6.3.2  Imaging 
DCE-CT was performed as described in section 2.3.1. Volumetric DCE-CT of the 
thorax (as per section 2.3.1.1) was selected to assess changes in lung tumour 
vascularity, on a whole tumour basis, resulting from the combination treatment 
described above. Eight DCE-CT scans were performed for cohort 7 as follows: 2 
baseline pretreatment scans; further scans at 1 hour after radiotherapy (1 hour prior 
to administration of CA4P) and another at 4 hours after administration of CA4P were 
scheduled with the second, fourth and sixth fractions of radiotherapy and doses of 
CA4P.  
 
6.3.3  Statistical analysis 
Statistical comparison of changes in the DCE-CT derived parameters (blood volume 
and permeability surface area product) between time points were assessed using 
reproducibility analysis, as per section 2.3.1.3. To allow assessment of 
measurement reproducibility, the two initial pretreatment perfusion studies from 
each patient were analysed by the same observer for both studies, cross-
referencing between studies from the same patient to ensure similar tumour levels. 
This reproducibility statistic enabled the calculation of whether a change in blood 
volume or permeability surface area product post treatment for an individual patient 
or a group of patients was statistically significant.  
 
6.4  Results 
6.4.1 Lung Volumetric DCE- CT  
Six patients were treated in cohort 7: 3 males and 3 females, mean age 71 years 
(Range 61 to 83 years). The combination treatment was well tolerated, with no dose 
limiting toxicities (DLTs) produced. All of the six patients received the intended 6 
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fractions of radiotherapy, 6 doses of CA4P and underwent volumetric DCE-CT 
scanning as planned; there were 48 CT studies for analysis from the 6 patients 
treated. An example of the colour DCE-CT parametric maps for 1 patient is shown in 
Figure 6.1. 
 
6.4.2  Reproducibility  
The reproducibility statistics for both blood volume and permeability surface area 
product are shown in Table 6.1. These were derived from the baseline volumetric 
DCE-CT scans from 24 patients with NSCLC in the UKR-104 study; 6 patients in 
cohort 1, 4 patients in cohort 2, 6 patients in cohort 7 and 8 patients in a 
radiotherapy alone control group. The Kendall’s tau test confirmed the 
proportionality of error on the mean value for both parameters, indicating 
dependence of error on the mean. As a result of this, both parameters were 
logarithmically transformed.  
 
The percentage group change, in each parameter resulting from therapy, required to 
achieve significance at the 95% level, was calculated for the different cohort sizes. 
For blood volume a change greater than –21.5% to 27.4% was required for cohort 7 
(n=6), a change greater than –18.9% to 23.4% for the combined cohorts 1 and 2 
(n=8), and a change greater than –25.7% to 34.6% was required for cohort 2 alone 
(n=4). For permeability surface area product a change greater than –11.4% to 
12.9% was required for cohort 7 (n=6), a change greater than –10.0% to 11.1% for 
the combined cohorts 1 and 2 (n=8), and a change greater than –13.8% to 16.0% 
required for cohort 2 alone (n=4). 
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6.4.3  Blood Volume 
The blood volume (BV) results for the 6 patients in cohort 7 and the mean values 
and standard deviations for the cohort, at each of the time points where DCE-CT 
was performed, are shown in Tables 6.2 and 6.3.  These results were then plotted to 
produce the graph seen in Figure 6.2.  
 
In this cohort, following the second fraction of radiotherapy (2# RT), having received 
both the first fraction of radiotherapy and first dose of CA4P 3 days earlier, the mean 
blood volume increased significantly by 42.2%. Four of the 6 patients in the cohort 
had a rise in BV between these time points, yet only patient, BS37, had a significant 
individual increase (193.6%). A reduction in BV was seen for 4 patients after the 
second dose of CA4P (CA4P2), compared to 1 hour after the second fraction of 
radiotherapy. However, differing effects in BV were observed between these time 
points, with patient BS37 having a significant individual reduction of -57.5%, 
whereas patient JW35 had a significant individual rise of 110.9%. There were no 
significant individual changes after the second dose of CA4P compared to the mean 
baseline (MB). The only other group change observed that was significant on 
reproducibility testing was the change in blood volume after the sixth fraction of 
radiotherapy compared with 4 hours after the fourth dose of CA4P (CA4P4), with a 
mean increase of 36.8%.  
 
Further significant individual changes in blood volume compared to previous time 
points were observed for patient JW35: a reduction of -48% at 4 hours after the 
fourth dose of CA4P, an increase of 259% after the sixth fraction of radiotherapy (6# 
RT) and a reduction of -50.7% at four hours after the sixth dose of CA4P (CA4P6). 
Again compared to previous time points, patient RD32 had a significant individual 
decrease of -74.3% after the sixth fraction of radiotherapy, and a significant 
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individual increase of 107.4%, 4 hours after the sixth dose of CA4P. Further to this, 
patient RD32 had a significant increase of 118.8% 4 hours after the fourth dose of 
CA4P, compared to mean baseline. The only other significant change seen was 
patient AA34 after the fourth fraction of radiotherapy, with a reduction of -47.1%, 
compared to mean baseline.  
 
The blood volume (BV) results for 8 patients from cohorts 1 and 2, in addition to the 
group mean values for the combined cohorts, are shown in Tables 6.4 and 6.5.  
These results were then plotted to produce the graph seen in Figure 6.3. There were 
no significant group changes compared with either mean baseline or the previous 
time point, for any of the eight patients. The only significant individual change 
produced was a reduction of 46.9% compared to mean baseline, with patient HC07 
at 1 hour after the sixth fraction of radiotherapy (6# RT). 
 
6.4.4  Permeability surface area product 
The permeability surface area product (PS) results for the 6 patients and the mean 
values and standard deviations for the cohort, at each of the time points where 
DCE-CT was performed, are shown in Tables 6.6 and 6.7.  These results were then 
plotted to produce the graph seen in Figure 6.4. 
 
A significant group increase of 20.3% in the whole tumour permeability surface area 
product was seen 1 hour after the second fraction of radiotherapy (2# RT), the 
patients having received both the first fraction of radiotherapy and first dose of CA4P 
3 days earlier. Of the 6 patients in cohort 7, 4 had a rise in PS, with patient BS37 
having a significant individual increase (77.8%), compared to mean baseline (MB), 
and one patient showing no change. At 4 hours after the second dose of CA4P 
(CA4P2) compared to after the second fraction of radiotherapy, PS was reduced for 
5 out of the 6 patients, patient BS37 having a significant individual reduction of -
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30%. However, patient RD32 was noted to have a significant rise (50%) at this time 
point, compared to after the second fraction of radiotherapy and mean baseline; 
these 2 values being identical.  
After the fourth fraction of radiotherapy (4# RT), the patients having received 3 
doses of CA4P previously, 4 of the 6 patients showed an increase in PS. The 
increase for patient JS33, was significant compared to 4 hours after the second 
dose of CA4P (35.5%) and also mean baseline (40%). However, a significant 
individual decrease in whole tumour PS (–33.3%), compared to 4 hours after the 
second dose of CA4P, was also observed at this time point for patient RD32. The 
only other significant group changes observed after this point were a rise of 14.8% 
at 4 hours after the fourth dose of CA4P (CA4P4) and a rise of 14.6% after the sixth 
dose of CA4P (CA4P6), both significant in comparison with mean baseline. Patient 
JW35 had a significant individual decrease in PS after the sixth fraction of 
radiotherapy (6# RT), compared with the previous time point (–27.3%) and with 
mean baseline (54.4%). At the same time point, a significant increase in PS was 
noted for patient AA34 (37.9%), in comparison to mean baseline, with this significant 
increase maintained at 4 hours after the subsequent sixth dose of CA4P. Patient 
AL31 had significant decreases in PS, compared to mean baseline, at 4 hours after 
the fourth dose of CA4P (-26.0%) and after the sixth fraction of radiotherapy (-
39.7%). 
 
The permeability surface area (PS) results for 8 patients from cohorts 1 and 2, in 
addition to the mean values for the combined cohorts, are shown in Tables 6.8 and 
6.9. These results were then plotted to produce the graph seen in Figure 6.5. 
Significant group changes were seen 1 hour after the second fraction of 
radiotherapy (2# RT) compared to mean baseline (MB), with a 14.6% increase in 
whole tumour PS. A significant group increase of 18.9% was also produced 1 hour 
after the fourth fraction of radiotherapy (4#RT), compared to 4 hours after the first 
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dose of CA4P (CA4P1). Significant individual changes in PS were also observed in 
cohorts 1 and 2. Significant rises were seen in PS after the second fraction of 
radiotherapy, compared with mean baseline, for patients FR03 (45.3%) and SF06 
(39.38%), although 4 hours after the first dose of CA4P they had changes in 
different directions, with a significant decrease (–31.4%) compared with the previous 
time point and a significant rise (74.1%) compared to mean baseline, respectively. 
Patient SD12 had a significant decrease in PS after the first dose of CA4P, 
compared to 1 hour after the second fraction of radiotherapy (-42.2%) and mean 
baseline (-34.9%). Following this decrease, patient SD12 then had a significant 
increase in PS of 49.8% 1 hour after the fourth fraction of radiotherapy (4# RT), 
compared with the previous time point. The only other significant individual change 
was patient HC07, where a reduction of –29.9% was seen after the sixth fraction of 
radiotherapy (6# RT) compared to 4 hours after the second dose of CA4P (CA4P2). 
 
6.5  Discussion  
Volumetric DCE-CT, an imaging biomarker of tumour vascularity, is being used 
increasingly to assess treatment related changes in tumour vasculature. DCE-CT 
has been used in this context in clinical trials of anti-angiogenic and other vascular 
directed therapies, including bevacizumab, endostatin, SU6668, L-NNA and the 
combination of AZD2171 and gefitinib ([Willett et al., 2004], [Thomas et al., 2004], 
[Xiong et al., 2004], [Ng et al., 2007c], [Meijerink et al., 2007]). Whole tumour 
measurements, have been made possible by novel volumetric techniques, which 
enable superior assessment of the spatial heterogeneity that exists within tumours.  
 
Previously some early phase clinical trials utilising volumetric techniques have 
examined the vascular effects in NSCLC of radiotherapy alone and in combination 
with a single dose of CA4P ([Ng et al., 2007b], [Ng et al., 2007a]). In this work, we 
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have built upon these previous studies, assessing the changes resulting from 
treatment with radiotherapy and the increased dose intensity of CA4P: from single 
dose to weekly then twice weekly. Whilst this chapter focuses on the final cohort of 6 
patients, within the whole UKR-104 study there were 24 NSCLC patients with the 
required two baseline scans, derived from 3 treatment and 1 control cohorts, from 
which reproducibility could be assessed, to determine the extent of treatment-related 
change required to indicate significance on an individual and group basis. This was 
done for  whole tumour blood volume and permeability surface area product in the 
patients from the 3 treatment cohorts; with the increased number of patient data 
providing more accurate assessment of the intra-tumoural variability in derived 
parameters with the volumetric DCE-CT technique in NSCLC (Bland and Altman, 
1996a,b,c). Given the marked heterogeneity that exists in tumour vascularity and 
blood flow between different tumours and in the same tumour at different time 
points, this is an important step. It also enables potential confounding patient 
factors, including variability in cardiac output or haemoglobin, to be taken into 
account. In addition to their role in the UKR-104 study, these measures of 
reproducibility will allow the significance of changes in volumetric DCE-CT 
parameters in NSCLC to be assessed in future studies utilising this technique at our 
centre.  
 
For all the NSCLC treatment cohorts in this study, the first DCE-CT scan during 
treatment was performed after the second fraction of radiotherapy. This provides an 
interesting point for comparison as cohort 7 had already received a dose of CA4P 
following the first fraction of radiotherapy, whereas cohorts 1 and 2 had not received 
any prior CA4P. A significant group increase in blood volume was seen for cohort 7, 
yet not the first 2 cohorts. The only patient to have a significant individual rise in 
blood volume was also in cohort 7. Receiving a dose of CA4P 72 hours previously 
did not impede this increase in blood volume, which could be due to greater blood 
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flow in the remaining larger vessels, resulting from the smaller and more immature 
blood vessels of the tumour being damaged by CA4P (Tozer et al., 2001). This 
effect on tumour blood volume was not seen in cohort 2 after the fourth fraction of 
radiotherapy, when they had received a dose of CA4P 1 week previously. It would 
suggest that this improvement in tumour blood flow in larger vessels post CA4P is 
due to a transient functional change, with a return to the more chaotic vascular state 
after 1 week. However, it could be that, as only 4 patients had volumetric DCE-CT 
scans in cohort 2, a similar effect is produced but has not been detected due to the 
small sample size. 
 
A different pattern was observed with permeability surface area product after the 
second fraction of radiotherapy. Significant group increases were seen in cohort 7 
and also in cohorts 1 and 2, seemingly independent of whether they had received a 
previous dose of CA4P or not. A further significant group increase in permeability 
surface area product after the fourth fraction of radiotherapy was observed with 
cohorts 1 and 2, but was not seen in cohort 7 or in any of the cohorts after the sixth 
fraction of radiotherapy. This suggests that it is the first dose of concurrent CA4P 
that has the greatest effect, further enhancing the increase in permeability of the 
tumour vasculature resulting from radiotherapy. The diminishing of this effect with 
further doses of CA4P may arise from the loss of small blood vessels within the 
tumour, due to the CA4P-induced disruption of interphase microtubules in 
endothelial cells; these small vessels being more sensitive to its vascular disruptive 
effects (Tozer et al., 2001).  
 
Indicative of the expected vascular shutdown produced by VDAs, individual 
decreases in whole tumour blood volume were produced at 4 hours following the 
administration of CA4P for 4 of the 6 patients in cohort 7 (after the second dose of 
CA4P) and 5 of the 8 patients in the combined cohorts 1 and 2 (after the first dose of 
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CA4P). Despite this, the only significant decreases were observed in cohort 7 and 
occurred in patients where significant individual increases in blood volume had been 
previously observed, following the commencement of radiotherapy. These findings 
are in keeping with sensitisation of the tumour vasculature to the effects of CA4P by 
radiotherapy, an effect that may be more pronounced in tumours sensitive to the 
effects of CA4P. Tumours with increased vascular permeability have been shown to 
be more susceptible to vascular disruptive therapies and in these experiments we 
have seen that radiotherapy increases both tumour blood volume and permeability 
(Beauregard et al., 2001). It is possible that these vascular changes reflect 
treatment-induced enhanced endothelial cell damage, adding support for combining 
CA4P and radiotherapy, especially as radiation-induced damage to the tumour 
vasculature is known to be an important determinant of tumour cell survival (Garcia-
Barros et al., 2003). 
 
In preclinical studies, CA4P has been shown to increase tumour vascular 
permeability through disruption of the molecular engagement of endothelial cell-
specific junctional molecules, including VE-cadherin (Vincent et al., 2005). 
Significant rises in permeability surface area product after CA4P were seen with 
patients RD32 and JW35, followed by a significant decrease after the subsequent 
fraction of radiotherapy, yet patient BS37 displayed the exact opposite effect with a 
decrease after CA4P and a rise after radiotherapy. The twice weekly scheduling of 
concurrent CA4P (cohort 7) produced a significant rise in permeability surface area 
product for 5 of the 6 patients, compared with only 2 of the eight patients receiving a 
once weekly schedule of CA4P (cohorts 1 and 2). This difference is, however, not 
statistically significant and whether a true additive benefit is being observed with the 
more dose dense regimen remains uncertain.  
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6.5  Conclusion 
In this experiment we were able to detect significant treatment-induced changes in 
both whole tumour blood volume and permeability surface area product in these 
cases of NSCLC. Through inclusion of DCE-CT data from 24 patients, we were able 
to accurately determine the reproducibility of the volumetric technique at our centre. 
We have observed a greater proportion of significant group increases in blood 
volume and permeability surface area product plus a greater number of significant 
changes in these parameters in cohort 7, with the twice weekly scheduling of CA4P 
combined with twice weekly fractions of radiotherapy, compared to the single dose 
and weekly scheduling used in cohorts 1 and 2 respectively. The increase seen in 
functional tumour vascular leakage after radiotherapy was, however, lost in the twice 
weekly scheduling of CA4P after the second fraction, and was only present with the 
weekly scheduling of CA4P after the fourth fraction.  
 
Given the small number of patients in each treatment cohort, it is impossible to fully 
establish the significance of these observed differences. It is very likely that 
differences in tumour cell type, grade, stage and tumour volume may contribute to 
these findings. Our data would support the hypothesis that enhanced endothelial cell 
damage results from the combination of radiotherapy and concurrent administration 
of CA4P in advanced NSCLC, without any significant overlapping or enhanced 
acute toxicity. Further phase 2 studies are required to fully establish the role for this 
combination therapy in NSCLC, using either weekly CA4P at a dose of 50mg/m2 for 
standard daily radiotherapy fractionations (5 days per week) or, potentially, twice 
weekly CA4P, at a dose of 50mg/m2, if using a twice weekly radiotherapy 
fractionation, as in this study. 
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Colour parametric maps of DCE-CT derived whole tumour blood volume (BV) for 
patient BS37, who received twice weekly CA4P and RT, as part of Cohort 7. The 
yellow arrow points to the left apical lung primary tumour. An increase in blood 
volume (compared to baseline) is seen in the lung tumour 1 hour after the second 
fraction of radiotherapy (2# RT), then a decrease at 4 hours after the subsequent 
(second) dose of CA4P (CA4P2), on the same day. In comparison to CA4P2, only 
slight changes were observed in BV with the next DCE-CT scan, 1 hour after the 
fourth fraction of radiotherapy (4# RT). 
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Mean (SD) 11.49 (4.05) 5.82 (2.14) 
Mean difference 0.16 -1.19 
95% limits of agreement  -25.7% to 34.5% -44.8% to 81.1% 
WSD 0.11a 0.21a
WCV (%) 11.3a 23.9a
Repeatability 0.30 0.59 
   
aLn transformed data  
SD – standard deviation; WCV – within subject coefficient of variation; WSD – within 
subject standard deviation 
 
Table 6.1 
Reproducibility and repeatability statistics from paired studies performed on 24 
patients, with NSCLC due to receive high dose palliative radiotherapy, measuring 
whole tumour permeability surface area product (PS) and blood volume (BV). 
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Graph of median whole tumour blood volume for NSCLC patients receiving twice 
weekly CA4P and RT (Cohort 7), plotted at the following time points: MB- mean 
baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P2 – 4 hours after 
the second dose of CA4P; 4# RT- 1 hour after fourth fraction of radiotherapy; 
CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after sixth fraction of 
radiotherapy; CA4P6 – 4 hours after the sixth dose of CA4P. 
 
 211
  MB 2# RT change (%) CA4P2 change (%) 4# RT change (%) 
AL31 7.20 10.00 38.89 8.10 12.50 6.20 -13.89 
RD32 4.8 7.90 64.58 6.70 39.58 6.80 41.67 
JS33 7.55 8.30 9.93 8.80 16.56 11.00 45.70 
AA34 4.35 3.10 -28.74 2.90 -33.33 2.30 -47.13a
JW35 8.55 6.40 -25.15 13.50 57.89 7.50 -12.28 
BS37 7.05 20.70 193.62a 8.80 24.82 9.10 29.08 
Mean 6.58 9.40 42.19b 8.13 19.67 7.15 7.19 
        
  CA4P4 change (%) 6# RT change (%) CA4P6 change (%) 
AL31  6.20 -13.89 8.20 13.89 8.20 13.89 
RD32  10.50 118.75a 2.70 -43.75 5.60 16.67 
JS33  10.30 36.42 7.70 1.99 11.80 56.29 
AA34  3.40 -21.84 5.20 19.54 5.40 24.14 
JW35  3.9 -54.39a 14 63.74 6.9 -19.30 
BS37  8.30 17.73 6.30 -10.64 8.70 23.40 
Mean  7.10 13.80 7.35 7.46 7.77 19.18 
 
aSignificant individual change in BV bSignificant group change in BV 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P2 – 4 
hours after the second dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P6 – 4 hours after the sixth dose of CA4P. 
 
Table 6.2  
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from mean baseline for NSCLC patients receiving twice weekly CA4P and 
RT (UKR104 cohort 7). 
 212
  MB 2# RT change (%) CA4P2 change (%) 4# RT change (%) 
AL31 7.20 10.00 38.89 8.10 -19.00 6.20 -23.46 
RD32 4.8 7.90 64.58 6.70 -15.19 6.80 1.49 
JS33 7.55 8.30 9.93 8.80 6.02 11.00 25.00 
AA34 4.35 3.10 -28.74 2.90 -6.45 2.30 -20.69 
JW35 8.55 6.40 -25.15 13.50 110.94a 7.50 -44.44 
BS37 7.05 20.70 193.62a 8.80 -57.49a 9.10 3.41 
Mean 6.58 9.40 42.19b 8.13 3.14 7.15 -9.78 
        
  CA4P4 change (%) 6# RT change (%) CA4P6 change (%) 
AL31  6.20 0.00 8.20 32.26 8.20 0.00 
RD32  10.50 54.41 2.70 -74.29a 5.60 107.41a
JS33  10.30 -6.36 7.70 -25.24 11.80 53.25 
AA34  3.40 47.83 5.20 52.94 5.40 3.85 
JW35  3.9 -48.00a 14 258.97a 6.9 -50.71a
BS37  8.30 -8.79 6.30 -24.10 8.70 38.10 
Mean  7.10 6.51 7.35 36.76b 7.77 25.31 
  
aSignificant individual change in BV bSignificant group change in BV 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P2 – 4 
hours after the second dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P6 – 4 hours after the sixth dose of CA4P. 
 
Table 6.3   
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from previous time point for NSCLC patients receiving twice weekly CA4P 
and RT (UKR104 cohort 7). 
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Graph of median whole tumour blood volume for NSCLC patients receiving single 
dose or weekly CA4P and RT (Cohorts 1 + 2), plotted at the following time points: 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P1 – 4 
hours after the first dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
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  MB 2# RT change (%) CA4P1 change (%)     
FR03 4.79 7.50 56.58 5.67 18.37     
CM04 8.79 7.47 -15.02 8.50 -3.30     
RM05 4.34 4.29 -1.15 4.47 3.00     
SF06 8.02 9.16 14.29 6.83 -14.78     
HC07 6.76 8.53 26.18 6.93 2.51     
CY09 7.67 8.81 14.86 7.38 -3.78     
AI10 5.89 6.66 13.17 5.59 -5.01     
SD12 8.02 7.57 -5.55 4.80 -40.11     
Mean 6.78 7.50 12.92 6.27 -5.39     
          
  4# RT change (%) CA4P2 change (%) 6# RT change (%) CA4P3 change (%)
HC07  6.15 -9.02 5.62 -16.86 3.59 -46.89a 3.81 -43.64 
CY09  7.05 -8.08 5.96 -22.29 6.83 -10.95 5.13 -33.12 
AI10  6.56 11.47 6.15 4.50 6.92 17.59 5.74 -2.46 
SD12  8.66 8.05 8.30 3.56 7.31 -8.80 7.83 -2.31 
Mean  7.11 0.60 6.51 -7.77 6.16 -12.26 5.63 -20.38 
 
aSignificant individual change in BV bSignificant group change in BV 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P1 – 4 
hours after the first dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 6.4   
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from mean baseline for NSCLC patients receiving single dose and weekly 
CA4P and RT (UKR104 cohorts1+2). 
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  MB 2# RT change (%) CA4P1 change (%)     
FR03 4.79 7.50 56.58 5.67 -24.40     
CM04 8.79 7.47 -15.02 8.50 13.79     
RM05 4.34 4.29 -1.15 4.47 4.20     
SF06 8.02 9.16 14.29 6.83 -25.44     
HC07 6.76 8.53 26.18 6.93 -18.76     
CY09 7.67 8.81 14.86 7.38 -16.23     
AI10 5.89 6.66 13.17 5.59 -16.07     
SD12 8.02 7.57 -5.55 4.80 -36.59     
Mean 6.78 7.50 12.92 6.27 -14.94     
          
  4# RT change (%) CA4P2 change (%) 6# RT change (%) CA4P3 change (%)
HC07  6.15 -11.26 5.62 -8.62 3.59 -36.12 3.81 6.13 
CY09  7.05 -4.47 5.96 -15.46 6.83 14.60 5.13 -24.89 
AI10  6.56 17.35 6.15 -6.25 6.92 12.52 5.74 -17.05 
SD12  8.66 80.42 8.30 -4.16 7.31 -11.93 7.83 7.11 
Mean  7.11 20.51 6.51 -8.62 6.16 -5.23 5.63 -7.18 
  
aSignificant individual change in BV bSignificant group change in BV  
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P1 – 4 
hours after the first dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 6.5   
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from previous time point for NSCLC patients receiving single dose and 
weekly CA4P and RT (UKR104 cohorts1+2). 
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Figure 6.4  
Graph of median whole tumour permeability surface area product for NSCLC 
patients receiving twice weekly CA4P and RT (Cohort 7), plotted at the following 
time points: MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; 
CA4P2 – 4 hours after the second dose of CA4P; 4# RT- 1 hour after fourth fraction 
of radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after 




 MB 2# RT change (%) CA4P2 change (%) 4# RT change (%) 
AL31 18.25 16.50 -9.59 14.00 -23.29 15.00 -17.81 
RD32 9.00 9.00 0.00 13.50 50.00a 9.00 0.00 
JS33 15.00 17.00 13.33 15.50 3.33 21.00 40.00a
AA34 7.25 8.00 10.34 7.00 -3.45 8.00 10.34 
JW35 14.25 18.50 29.82 14.50 1.75 19.00 33.33 
BS37 11.25 20.00 77.78a 14.00 24.44 11.50 2.22 
Mean 12.50 14.83 20.28b 13.08 8.80 13.92 11.35 
        
  CA4P4 change (%) 6# RT change (%) CA4P6 change (%) 
AL31  13.50 -26.03a 11.00 -39.73a 14.50 -20.55 
RD32  9.00 0.00 8.00 -11.11 9.50 5.56 
JS33  18.50 23.33 17.50 16.67 18.50 23.33 
AA34  8.50 17.24 10.00 37.93a 10.00 37.93a
JW35  22.00 54.39a 16.00 12.28 16.00 12.28 
BS37  13.50 20.00 13.50 20.00 14.50 28.89 
Mean  14.17 14.82b 12.67 6.01 13.83 14.57b
  
aSignificant individual change in PS bSignificant group change in PS 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P2 – 4 
hours after the second dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P6 – 4 hours after the sixth dose of CA4P. 
 
Table 6.6   
DCE-CT derived permeability surface area product (PS) values (ml/100ml/min) and 
percentage change from mean baseline for NSCLC patients receiving twice weekly 




 MB 2# RT change (%) CA4P2 change (%) 4# RT change (%) 
AL31 18.25 16.50 -9.59 14.00 -15.15 15.00 7.14 
RD32 9.00 9.00 0.00 13.50 50.00a 9.00 -33.33a
JS33 15.00 17.00 13.33 15.50 -8.82 21.00 35.48a
AA34 7.25 8.00 10.34 7.00 -12.50 8.00 14.29 
JW35 14.25 18.50 29.82 14.50 -21.62 19.00 31.03 
BS37 11.25 20.00 77.78a 14.00 -30.00a 11.50 -17.86 
Mean 12.50 14.83 20.28b 13.08 -6.35 13.92 6.13 
        
  CA4P4 change (%) 6# RT change (%) CA4P6 change (%) 
AL31  13.50 -10.00 11.00 -18.52 14.50 31.82 
RD32  9.00 0.00 8.00 -11.11 9.50 18.75 
JS33  18.50 -11.90 17.50 -5.41 18.50 5.71 
AA34  8.50 6.25 10.00 17.65 10.00 0.00 
JW35  22.00 15.79 16.00 -27.27a 16.00 0.00 
BS37  13.50 17.39 13.50 0.00 14.50 7.41 
Mean  14.17 2.92 12.67 -7.44 13.83 10.61 
 
aSignificant individual change in PS bSignificant group change in PS 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P2 – 4 
hours after the second dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P6 – 4 hours after the sixth dose of CA4P. 
 
Table 6.7   
DCE-CT derived permeability surface area product (PS) values (ml/100ml/min) and 
percentage change from previous time point for NSCLC patients receiving twice 
weekly CA4P and RT (UKR104 cohort 7). 
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Graph of median whole tumour permeability surface area product for NSCLC 
patients receiving single or weekly CA4P and RT (Cohorts 1 + 2), plotted at the 
following time points: MB- mean baseline; 2# RT- 1 hour after second fraction of 
radiotherapy; CA4P1 – 4 hours after the first dose of CA4P; 4# RT- 1 hour after 
fourth fraction of radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# 




  MB 2# RT change (%) CA4P1 change (%)     
FR03 9.25 13.44 45.30a 9.22 -0.32     
CM04 16.60 12.56 -24.34 14.59 -12.11     
RM05 12.58 12.46 -0.91 13.59 8.07     
SF06 12.13 16.90 39.38a 21.11 74.10a     
HC07 9.23 10.33 11.98 10.41 12.85     
CY09 11.68 13.67 17.09 11.91 2.01     
AI10 9.97 11.50 15.35 9.18 -7.92     
SD12 11.75 13.23 12.60 7.65 -34.89a     
Mean 11.65 13.01 14.55b 12.21 5.22     
          
  4# RT change (%) CA4P2 change (%) 6# RT change (%) CA4P3 change (%)
HC07  11.13 20.65 10.34 12.09 7.25 -21.41 7.99 -13.39 
CY09  13.92 19.23 18.09 54.95 16.33 39.87 17.05 46.04 
AI10  9.35 -6.22 10.38 4.11 10.54 5.72 12.82 28.59 
SD12  11.46 -2.47 13.14 11.83 15.61 32.85 15.22 29.53 
Mean  11.47 7.80 12.99 20.74 12.43 14.26 13.27 22.69 
  
aSignificant individual change in PS bSignificant group change in PS 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P1 – 4 
hours after the first dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 6.8   
DCE-CT derived permeability surface area product (PS) values (ml/100ml/min) and 
percentage change from mean baseline for NSCLC patients receiving single dose 
and weekly CA4P and RT (UKR104 cohorts1+2). 
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  MB 2# RT change (%) CA4P1 change (%)     
FR03 9.25 13.44 45.30a 9.22 -31.40a     
CM04 16.60 12.56 -24.34 14.59 16.16     
RM05 12.58 12.46 -0.91 13.59 9.07     
SF06 12.13 16.90 39.38a 21.11 24.91     
HC07 9.23 10.33 11.98 10.41 0.77     
CY09 11.68 13.67 17.09 11.91 -12.87     
AI10 9.97 11.50 15.35 9.18 -20.17     
SD12 11.75 13.23 12.60 7.65 -42.18a     
Mean 11.65 13.01 14.55b 12.21 -6.96     
          
  4# RT change (%) CA4P2 change (%) 6# RT change (%) CA4P3 change (%)
HC07  11.13 6.92 10.34 -7.10 7.25 -29.88a 7.99 10.21 
CY09  13.92 16.88 18.09 29.96 16.33 -9.73 17.05 4.41 
AI10  9.35 1.85 10.38 11.02 10.54 1.54 12.82 21.63 
SD12  11.46 49.80a 13.14 14.66 15.61 18.80 15.22 -2.50 
Mean  11.47 18.86b 12.99 12.13 12.43 -4.82 13.27 8.44 
 
aSignificant individual change in PS bSignificant group change in PS 
MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; CA4P1 – 4 
hours after the first dose of CA4P; 4# RT- 1 hour after fourth fraction of 
radiotherapy; CA4P2 – 4 hours after the second dose of CA4P; 6# RT- 1 hour after 
sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 6.9   
DCE-CT derived permeability surface area product (PS) values (ml/100ml/min) and 
percentage change from previous time point for NSCLC patients receiving single 





Tumour vascular effects of combined vascular 
disruption, EGFR inhibition and radiation in 
Head and Neck cancer. 
 
7.1  Aims  
x To determine tumour vascular effects, using single level perfusion CT in 
Head and Neck squamous cell carcinoma, of radical radiotherapy in 
combination with weekly combretastatin A-4 phosphate and cetuximab. 
x To detect changes in cytokine production and blood composition in patients 
with Head and Neck squamous cell carcinoma receiving radical radiotherapy 
in combination with weekly combretastatin A-4 phosphate and cetuximab. 
 
7.2  Introduction 
This chapter contains details of clinical experiments using DCE-CT to assess the 
tumour vascular changes resulting from the administration of the VDA CA4P, in 
addition to radiotherapy and the EGFR inhibitor, cetuximab, in patients with SCCs of 
the head and neck region. 
 
In the treatment of locally advanced SCC of the head & neck, radiotherapy is 
commonly employed, either preoperatively or postoperatively. Whilst 
hyperfractionated and accelerated regimens have been extensively studied, the 
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standard fractionation used in the UK is 2Gy per fraction for 6.5 to 7 weeks. 
However, radiotherapy alone is no longer the standard of care for the treatment of 
this patient group. A large meta-analysis, using individual patient data, most recently 
updated in 2009, examining the use of cisplatin-based chemotherapy in head and 
neck cancer has shown a more pronounced benefit with concomitant chemotherapy 
compared to induction chemotherapy, producing a hazard ratio of death of 0.81 
(p<0.0001) and an absolute benefit 6.5% at 5 years (Pignon et al., 2009). 
Concomitant cetuximab has also been shown to improve outcome in locally 
advanced head and neck cancer, producing a median overall survival of 49 months 
compared to 29.3 months for radiotherapy alone; hazard ratio of 0.74 (p=0.03) 
(Bonner et al., 2006).  
 
As previously discussed in Chapter 4, there have been preclinical studies that have 
demonstrated enhanced anti-tumour effects with the addition of a VDA to combined 
radiotherapy and EGFR inhibition ([Bozec et al., 2006], [Raben et al., 2004]). In the 
experiments described in Chapter 4, using the head and neck squamous cell 
carcinoma (HNSCC) tumour model FaDu, enhanced anti-tumour effect was 
observed with cetuximab, CA4P and radiotherapy; this combination being the only 
treatment to produce significant tumour growth delay compared to radiation alone. 
As part of a phase Ib study, we undertook to determine whether this triple 
combination was tolerable in the clinical setting and to explore the resultant effects 
on the tumour vasculature, using DCE-CT imaging and circulatory biomarkers. 
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7.3  Methods 
7.3.1  Patient selection and recruitment 
All patients were recruited as part of the study entitled “Phase Ib trial of CA4P 
(combretastatin A-4 phosphate) in combination with radiotherapy in patients with 
advanced cancer of the lung, head & neck or prostate: CA4P protocol number 
UKR104”. The full inclusion and exclusion criteria in the UKR-104 protocol for all 
cohorts receiving treatment with radiotherapy and CA4P are listed in Appendix B. 
The analysis of one cohort of this phase 1b clinical trial is examined in this chapter, 
the treatment scheduling of which is shown in Table 2.1. It was intended that 6 
patients would be treated in each of the treatment cohorts, provided the combination 
treatment was well tolerated and no dose limiting toxicities (DLTs) were observed. 
The stopping criteria were defined as 2 patients in a single cohort experiencing 
DLTs.  
 
Patients with histologically confirmed squamous cell carcinoma of the head and 
neck, suitable for radical treatment, were prospectively recruited; fulfilling the criteria 
for inclusion in the study, they proceeded to receive radical radiotherapy to the head 
and neck, 64 to 70Gy in 32 to 35 fractions over 6.5 to 7 weeks (as per section 
2.2.1.2). This was delivered in combination with CA4P (as per section 2.2.2), 
50mg/m2 i.v. after the final fraction of radiotherapy each week; it was intended that 
each patient was to receive a total of 7 doses of CA4P. Concurrent cetuximab was 
also delivered, as per section 2.2.3, with a loading dose given one week prior to 
radiotherapy and further doses given weekly for the duration of radiotherapy.  
 
7.3.2  Imaging 
Single level DCE-CT was used to assess changes in tumour vascularity, resulting 
from these combination therapies, using the technique described in section 2.3.1. 
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Up to 9 DCE-CT scans were performed at the following time points:  2 baseline 
pretreatment scans; 4 to 6 days after loading dose of cetuximab on the day of but 
prior to first fraction of radiotherapy; 1 hour after the final fraction of radiotherapy in 
the first week (1 hour prior to administration of CA4P), 4 hours after the first dose of 
CA4P and 72 hours after the first dose of CA4P; 1 hour after the final fraction of 
radiotherapy in week 5 (1 hour prior to administration of CA4P), with further CTs at 4 
hours and 72 hours after the subsequent dose of CA4P. 
 
7.3.3  Blood sampling 
Following the insertion of a cannula, into a suitable forearm vein, 10 mls of blood 
was collected in EDTA tubes for full blood count and to provide plasma samples for 
ELISA (as per section 2.4). Blood samples were taken at four designated time points 
with the first dose of CA4P administered: preCA4P, 4 hours post CA4P, 6 to 8 hours 
post CA4P and 1 week post CA4P.   
 
7.3.4  Statistical analysis 
Statistical comparison of changes in blood count and cytokine parameters, between 
time points, were assessed using a paired samples t-test, as per section 2.6.4. 
 
7.4  Results 
7.4.1  Head and Neck Single Level DCE- CT 
Four patients were treated in this cohort, 3 males and 1 female, mean age 73 years 
(range 65 to 86 years). DLTs of myocardial ischaemia were observed in the third 
and fourth patients treated, after the third and fourth doses of CA4P respectively, 
which fulfilled the stopping criteria for the cohort, therefore no further patients were 
treated. Only the first patient in the cohort received the intended 7 doses of CA4P, 
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the third and fourth patients only receiving 3 and 4 doses respectively. These three 
patients completed the planned radiotherapy and cetuximab treatment. The second 
treated patient developed aspiration pneumonia, attributed to his radical 
radiotherapy, and whilst an inpatient with this problem, he experienced a fall, 
resulting in a fractured neck of femur. As a result of these complications the second 
patient received only 4 doses of CA4P (on weeks 1,2,3 and 5) and did not complete 
the intended radiotherapy or cetuximab treatments.  
 
There were 21 studies for analysis from 3 patients (6 studies each for the first and 
third patients and 9 studies for the second patient). The final three DCE-CT scans 
for the first patient were performed in the final week of the radiotherapy treatment, 
when it was noted that due to the complete response of his primary tumour no 
further measurements could be taken. Subsequently, there was rescheduling of the 
final 3 scans for the following patients in the cohort, initiating them at the end of the 
fifth week of radiotherapy. For the second patient the DCE-CT scans were 
undertaken as per the new schedule but the final scans were performed at the end 
of the fifth week with the fourth dose of CA4P, as the patient had missed one dose 
of CA4P in the previous week. The third patient did not have scans in the fifth week 
as the CA4P had been discontinued; due to the previously stated observed toxicity. 
The final patient in the cohort received her treatment as an adjuvant, with no 
residual macroscopic disease and was therefore not suitable for DCE-CT 
assessment of response. An example of the colour DCE-CT parametric maps for 1 
patient is shown in Figure 7.1. 
 
Due to only 3 patients having DCE-CT scanning, it was not possible to use 
reproducibility statistics to reliably ascertain the significances of any changes seen 
in the DCE-CT parameters. Descriptive analysis of the observed changes was 
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therefore undertaken. The changes in all parameters measured for the group mean 
and individual patients are summarised on Table 7.1. 
 
7.4.2  Blood Volume 
The median blood volume (BV) results for the 3 patients and the mean values for 
the cohort, at each of the time points where DCE-CT was performed, are shown in 
Tables 7.2 and 7.3.  These results were then plotted to produce the graph seen in 
Figure 7.2. 
 
No real change of any magnitude was seen in median tumour BV at 4 to 5 days 
after the loading dose of cetuximab (Cet) or 1 hour after the fifth fraction of 
radiotherapy (5#RT). A variable response was observed at 4 hours after the first 
dose of CA4P; patient JC36 had an individual increase of 84%, compared to mean 
baseline, and of 123.7%, compared to after the fifth fraction of radiotherapy, 
whereas the other 2 patients had decreases of –40.8% and –28.0% compared to 
mean baseline. Patient HC38 had an increase in BV of 127.9% at 72 hours after the 
first dose of CA4P (CA4P1), compared to 4 hours after the same dose of CA4P, 
although again JC36 showed changes in the other direction with a decrease of –
47.5%. HC38 had a further large increase of 95.2% at 1 hour after the twenty-fifth 
fraction of radiotherapy (25#RT), compared to mean baseline. 
 
7.4.3  Permeability surface area product  
The median permeability surface area product (PS) results for the 3 patients and the 
mean values for the cohort, at each of the time points where DCE-CT was 
performed, are shown in Tables 7.4 and 7.5. These results were then plotted to 
produce the graph seen in Figure 7.3. 
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At 4 to 5 days after the loading dose of cetuximab (Cet) and prior to the first fraction 
of radiotherapy, a reduction in group mean PS was produced of -10.2%, compared 
to mean baseline (MB). At this time point, patient GK39 had an individual decrease 
in PS of -40.0%, patient HC38 had a decrease of lesser magnitude and patient JC36 
actually had an increase of 19.7%, all compared to mean baseline. After the fifth 
fraction of radiotherapy (5#RT) there was a 20.3% increase in the group mean PS, 
compared to the previous time point (after the loading dose of cetuximab), with an 
increase of 42.3% seen with patient JC36 and of 25.0% with patient HC38. As seen 
before, a variation in response was observed; GK39 having a decrease of –43.9%, 
compared to patient JC36 who had an increase of 70.3%, both compared to mean 
baseline.  
 
Four hours after the first dose of CA4P (CA4P1), patient JC36 had an individual 
increase in PS of 110% compared to mean baseline and 20% compared to 1 hour 
after the fifth fraction of radiotherapy. Although this remained raised at 72 hours 
after the first dose of CA4P and prior to the sixth fraction of radiotherapy (72h 1), 
compared to mean baseline (104.4%), there was, in fact, a small decrease 
compared to the previous time point. There were small increases in the group mean 
PS at 4 hours (16.0%) and 72 hours (18.7%) after the first dose of CA4P. At these 
two time points patient GK39 had individual decreases in permeability surface area 
product; at 4 hours after CA4P a decrease of -57.6% compared to mean baseline 
and a decrease of –24.5% compared to 1 hour after the fifth fraction of radiotherapy, 
and then at 72 hours a decrease of –51.9% compared to mean baseline. 
 
At 1 hour after the twenty-fifth fraction of radiotherapy (25#RT) for patient HC38, 
there was an increase in PS compared to both mean baseline (25.3%) and 72 hours 
after the first dose of CA4P (21%). There were further individual increases for this 
patient at 4 hours after the fourth dose of CA4P of 55.3 % compared with mean 
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baseline and 24.0% compared with 1 hour after the twenty-fifth fraction of 
radiotherapy. Finally, at 72 hours after the fourth dose of CA4P, PS increased 
further to 82.15ml/100ml; a relatively large increase compared to mean baseline 
(75.6%), but no real change compared with the previous time point, 4 hours after the 
fourth dose of CA4P.  
 
7.4.4  Blood Flow 
The median blood flow (BF) results for the 3 patients and the mean values for the 
cohort, at each of the time points where DCE-CT was performed, are shown in 
Tables 7.6 and 7.7.  These results were then plotted to produce the graph seen in 
Figure 7.4. 
 
At 4 to 6 days after administration of the loading dose of cetuximab (Cet), patient 
GK39 demonstrated an individual increase in BF of 169.3% compared with mean 
baseline (MB). Despite no sizable changes observed with the 2 other patients, a 
group mean increase of 48.5% was still produced. After the fifth fraction of 
radiotherapy (5#RT), despite a slight reduction in blood flow for patient GK39 
compared with the previous time point, there was an individual increase for this 
patient (131.3%) and a group mean increase (55.1%) in blood flow compared to 
mean baseline. At four hours after the first dose of CA4P, there were comparatively 
large individual reductions in BF compared with 1 hour after the fifth fraction of 
radiotherapy seen for 2 patients: patient HC38 (-57.1%) and patient GK39 (-63.5%). 
This reduction in BF was not seen for all patients at this time point, with patient JC36 
having a significant individual increase compared with 1 hour after the fifth fraction 
of radiotherapy (95.5%) and mean baseline (91.7%). Following this, the individual 
increase in BF of greatest magnitude observed in this study was patient HC38 at 4 
hours after the fourth dose of CA4P, compared with 1 hour after the twenty-fifth 
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fraction of radiotherapy, with an increase of 87.2%. No other large individual or 
group changes in BF were observed.  
 
7.4.5  Blood Testing 
All four patients in cohort 6 underwent blood testing. Blood samples for first patient, 
JC36, were delayed and collected with the sixth dose of CA4P. The final three 
patients treated in the cohort all had sampling as planned, with the first dose of 
CA4P.  
 
7.4.6  Full Blood Count 
The results from the full blood count testing, undertaken for all four head and neck 
patients are shown in Table 7.8. The results for white cell count, neutrophil count, 
lymphocyte count and monocyte count, including the mean values, were then 
plotted to produce the graphs seen in Figures 7.5, 7.6, 7.7 and 7.8 respectively.  
 
All four patients demonstrated significant increases at 6 hours, compared to pre 
CA4P, in total white blood cells with a mean increase of 3.45 (p=0.0151), and 
neutrophils with a mean increase of 3.8 (p=0.0152). This compared to 4 hours after 
CA4P, when although there was an increase in the mean white cell and neutrophil 
counts, 2 patients (HC38 and GK39) in fact had a decrease in both of these 
parameters and these mean increases were not significant on paired t-testing 
(Figures 7.5 and 7.6). At 1 week post CA4P, both the white cell and neutrophil 
counts had decreased significantly compared with 6 to 8 hours after CA4P, with 
mean decreases of 4.5 (p=0.0031) and 4.6 (p=0.0033) respectively. There were no 
other significant decreases in these parameters between the various time points 
when samples were collected. 
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A significant reduction in lymphocyte count was seen at 4 hours after CA4P 
compared to preCA4P (Figure 7.7); a mean reduction of 0.275 (p=0.0222). At 4 
hours after CA4P all four patients had a decrease in lymphocyte count. There was a 
further reduction in the lymphocyte count for patient GK39 but an increase for JC36, 
between 4 hours and 6 to 8 hours, returning to the same level as preCA4P. The 
lymphocyte counts for the other 2 patients between these time points were 
unchanged and paired t-testing at 6 to 8 hours compared to preCA4P revealed only 
a non-significant trend towards a sustained decrease at 6 to 8 hours (p=0.0632). 
The monocyte count also significantly changed following administration of CA4P 
with a mean increase of 0.25 (p=0.0154) between 4 hours and 6 to 8 hours after 
CA4P; this rise being produced in all four patients (Figure 7.8). At 4 hours after 
CA4P compared to preCA4P, a mean decrease of -0.3 was produced, with 3 
patients having a decrease in monocyte count, although patient JC36 had a small 
increase, which was not statistically significant (p=0.1343). The same three patients 
had an increase between 4 hours and 1 week after CA4P, but, once again, their 
response differed from patient JC36, who had no change in the monocyte count 
between these time points, producing a mean increase of 0.25; a non-significant 
trend towards a sustained increase in monocyte count at 1 week (p=0.0632). No 
other significant changes in blood parameters, including basophils and eosinophils 
(data not shown in tables), were seen over the study time period. 
 
7.4.7  ELISA 
The results from the ELISA testing for the cytokines VEGF, VEGFR-1, G-CSF and 
SDF-1 are shown in Table 7.9. These results, including the mean values, were then 
plotted for each of the cytokines, to produce the graphs seen in Figures 7.9, 7.10, 
7.11 and 7.12 respectively. 
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A mean increase in VEGF between preCA4P and 4 hours after CA4P of 44 pg/ml 
(p=0.1203) was produced; 3 patients showing an increase and patient HC38 
showing no change (Figure 7.9). Between 4 hours and 6 to 8 hours after CA4P, a 
decrease in the mean by 24.75 pg/ml (p=0.0679) was produced; the only patient to 
show no decrease was HC38. By 1 week, the mean VEGF had increased by 16 
pg/ml compared to 6 to 8 hours after CA4P, with patient GK39 having a decrease, 
although this was not significant. The variability of response between the time points 
seen with VEGF was not observed with VEGFR1, where all 4 patients had a similar 
direction of change throughout the study period, except between 4 and 6 to 8 hours 
after CA4P, where patient JC36 had a decrease in VEGFR1, whereas the other 3 
showed rises (Figure 7.10). A highly significant mean increase was observed in 
VEGFR1 at 4 hours, compared to preCA4P, of 67.5 pg/ml (p=0.0108). At 6 to 8 
hours, a mean increase of 96.75 pg/ml (p=0.065), compared to preCA4P, was 
produced but this was not significant. There was a mean increase in VEGFR1 of 
29.25 pg/ml between 4 and 6 to 8 hours after CA4P, but this was also not 
significant. Significant decreases were seen at 1 week, compared to both 4 hours 
and 6 to 8 hours after CA4P, with mean decreases of 88.5 pg/ml (p=0.0252) and 
117.75 pg/ml (p=0.0061) respectively. 
 
The G-CSF results show a similar pattern of change, in mean concentration, to 
VEGFR1 (Figure 7.11). There was an increase in mean at 4 hours, further increase 
at 6 hours and a decrease at 1 week. These changes in direction of results were 
consistent for the same three patients at each time point but patient JC36 had 
changes in the opposite direction for each one. As a result, none of these changes 
were significant on paired t-testing. There were also no significant changes in SDF-1 
between the tested time points (Figure 7.12). The validity of the SDF-1 results are 
uncertain, as, after analysis had been undertaken, it came to light that a further 
centrifugation step of 10000g for 10 minutes should have been performed. This was 
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required to remove platelets as they express a receptor for SDF-1 and this may 
affect the results of the assay. 
 
7.5  Discussion  
The scheduling of CA4P in this chapter was the final escalation of weekly CA4P 
dose intensity in the UKR104 study. Of the seven treatment cohorts in the study, 4 
were delivered using radical radiotherapy with a once daily fractionation, 5 fractions 
per week. Previous prostate cohorts had received CA4P 50mg/m2, either as a single 
dose or weekly for 4 weeks, with the final cohort receiving 63mg/m2, also weekly for 
4 weeks. CA4P was delivered after the final fraction of each week, to allow a 
recovery time of at least 72 hours, prior to recommencement of radiotherapy the 
next week. The radical fractionation used in cohort 6 for the treatment of SCC of the 
head & neck was delivered over 6.5 to 7 weeks, which allowed escalation of 
concurrent CA4P, with patients scheduled to receive 7 weekly doses at 50mg/m2.  
 
Concomitant cetuximab was incorporated into the treatment schedule for cohort 6, 
as a result of treatment with radiotherapy alone being superseded by combination 
therapies. This monoclonal antibody targets EGFR, inhibiting cellular processes, 
including proliferation, but also indirectly inhibits angiogenesis. It has been 
demonstrated to reduce expression of the pro-angiogenic factors VEGF, IL-8 and 
bFGF ([Petit et al., 1997], [Perrotte et al., 1999]). By combining one of the current 
standards of care, (cetuximab and radiotherapy), with CA4P, a vascular disruptive 
agent directed at a different target and with a different set of documented side 
effects, this treatment was designed to incorporate both vascular disruptive and 
antiangiogenic strategies. To determine the vascular effects resulting from this 
treatment single level DCE-CT, blood count and cytokine parameters were 
examined. Single level DCE-CT was selected to monitor the vascular changes in 
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this cohort, taking into account the relative size of the primary tumours to be 
assessed and also to allow assessment of blood flow. This gave z-axis coverage, for 
the CT scanner with four detectors, of approximately 2cm. From the 3 patients 
assessed, no consistent trends in any of the DCE-CT parameters measured were 
seen, but large changes were detected both between time points and in comparison 
with baseline values.  
 
From Figure 7.2 the rapid increase in blood volume at 72h after the first dose of 
CA4P with patient HC38 is evident, in comparison to the low level at 4 hours post 
dose, with the blood volume increasing to a peak after the 25th fraction of 
radiotherapy. Decreases in blood volume, after the first and fourth doses of CA4P, 
were also seen with this patient. The use of DCE-CT allowed the identification of a 
reduction in the group mean PS, compared to mean baseline 4 to 5 days after the 
loading dose of cetuximab, followed by an increase after the fifth fraction of 
radiotherapy. The mean PS remained raised at 4 hours and 72 hours after the first 
dose of CA4P, with only changes of small magnitude between time points. However, 
at every time point, up to 72 hours after the first dose of CA4P, there were individual 
changes in the other direction to that seen with the group mean. Patient HC38 had 
no sizable individual change in PS until after the twenty-fifth fraction of radiotherapy, 
when there was a greater increase that persisted at 4 hours and 72 hours after the 
fourth dose of CA4P (Figure 7.3). For this patient, the cumulative effect of this 
combination treatment increased the tumour PS and resulted in no acute reduction 
in PS at four hours after the fourth dose of CA4P, compared to that seen after the 
first dose of CA4P. 
 
Discernible changes in BF also resulted from the combination of therapies, with a 
large rise in BF seen after the loading dose of cetuximab for patient GK39, which 
resulted in a large increase in the group mean, despite the other 2 patients showing 
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only small decreases in BF. The group mean increase at 1 hour after the fifth 
fraction of radiotherapy was mainly due to the magnitude of increase of BF observed 
with patient GK, compared to mean baseline, when there had, in fact, been a small 
reduction in blood flow for this patient between 4 to 5 days after the loading dose of 
cetuximab and the fifth fraction of radiotherapy. The BF for the other 2 patients at 
this time point both increased, showing a further variable response. The expected 
reduction in blood flow 4 hours after CA4P was observed, with large reductions for 
patient HC38 and patient GK39, but in keeping with the variability previously 
observed, patient JC36 had a large increase at this time point. 
 
There is an ongoing quest to identify circulatory biomarkers that may be easily 
extracted by relatively non-invasive diagnostic techniques, including circulating 
levels of endothelial progenitor cells (EPC), pro-angiogenic cytokines and receptors, 
and these are now being incorporated into early phase clinical trials of vascular 
directed therapies ([Shaked et al., 2006], [Bertolini et al., 2006], [Shaked et al., 
2009], [Vermeulen et al., 2002.], [Lowndes et al., 2008], [Zhu et al., 2009]). EPCs 
from the bone marrow are recruited to tumour sites by a number of chemokines, 
including VEGF, SDF-1 and angiopoietin ([Hattori et al., 2001], [Peichev et al., 
2000]). SDF-1 acts by binding to CXCR4 on circulating vasculogenic stem cells and 
facilitates their adhesion, migration and homing to the tumour microenvironment 
([Ceradini et al., 2004], [Burger and Kipps, 2006], [Folkins et al., 2009]). This 
interaction between SDF-1 and CXCR4 is not limited to vasculogenic stem cells, 
with similar effects described in both cancer stem cells and normal stem cells, 
including the mobilisation of polymorphonuclear neutrophils and haemopoietic 
progenitor cells from the bone marrow ([Kucia et al., 2005], [Pelus et al., 2005]). 
 
In this chapter, patients being treated with radical radiotherapy and cetuximab for 
SCCs of the head & neck, had significant increases in both neutrophil count (at 6 to 
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8 hours) and VEGFR1 (at 4 hours) after receiving CA4P, demonstrating the acute 
vasculogenic response resulting from the CA4P-induced damage to the tumour 
vasculature. In keeping with this, the graphs for neutrophils, VEGFR1 and G-CSF 
(Figures 7.6, 7.10 and 7.11) all show a similar shape in their mean curves and the 
mean curve for VEGF demonstrates an increase at 4 hours prior to a reduction at 6 
to 8 hours. All three parameters demonstrate a statistically significant decrease, 
returning to baseline, when assessed at 1 week after receiving CA4P. 
 
The changes seen for VEGF and G-CSF were often consistent for 3 patients, but 
due to the small numbers in the cohort, 100% of changes had to be in the same 
direction to achieve significance. The standard full blood count testing was sensitive 
enough to demonstrate these significant changes in neutrophil count, also reflected 
in the white cell count results. It was not possible to test for EPCs at the local 
hospital laboratory. Whether the significant reduction in lymphocyte count at 4 hours 
is related to this vasculogenic response is uncertain, but lymphopenia is a 
documented side effect of CA4P. It could also be due to a direct toxic effect or a 
sensitivity of the lymphocytes to the effects of CA4P. 
 
By using both imaging and circulatory biomarkers, this enabled confirmation of the 
varied responses seen between the different patients. At 4 hours post CA4P, patient 
JC36 had documented rises in tumour BV, PS and BF, and rises in neutrophil count, 
VEGF and VEGFR, which peaked at 4 hours. In addition, the concentration of GCSF 
had decreased; with a further reduction at 6 to 8 hours post CA4P. These findings 
contrast with patient HC38, who had decreases in tumour BV, PS and BF, plus 
decreased neutrophil count, increasing VEGFR and increasing GCSF; these three 
circulatory parameters then continued to increase, peaking at 6 to 8 hours. These 
differences in patient HC38, may have resulted from a less well vascularised and 
more necrotic tumour, which would, therefore, be more reliant on the vessels 
 237
 238
damaged by CA4P. A prolongation of the vasculogenic response, as seen with the 
further increases in neutrophil count and VEFR at 6 to 8 hours, may result from this 
increased vascular and tumour damage. 
 
7.6  Conclusion 
The experiments in this chapter have demonstrated that single level DCE-CT 
parameters can be used to detect acute changes in the vasculature of SCCs of the 
head & neck, undergoing treatment with radiotherapy, cetuximab and CA4P. 
However, a marked heterogeneity in the DCE-CT parameters was demonstrated, 
which may represent the inherent heterogeneity of the tumours. In this experiment, 
we have also harnessed the use of specific circulatory biomarkers and have 
demonstrated significant vasculogenic responses to CA4P- induced vascular 
damage; with significant acute rises in neutrophil count and VEGFR1. This indicates 
that the indirect antiangiogenic action of cetuximab does not prevent this 
vasculogenic response, in patients with SCC of the head & neck who are receiving 
radical radiotherapy, cetuximab and CA4P.  
 
The findings from this study were limited by the observed toxicity of increased 
myocardial ischaemia with these combined therapies. Prior to the combination being 
looked at again in the clinical setting, further preclinical studies are required to 
determine whether the detrimental normal tissue cardiovascular effects, produced 
by the combination of CA4P and cetuximab, can be modulated by anti-hypertensive 












































































































































































































































































































           
  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
Mean BV 62.69 57.38 -7.17 59.16 0.17 71.04 20.54 66.57 24.84 
Mean PS 36.14 31.35 -10.19 38.65b 20.30 37.68 -5.41 39.19 6.57 
Mean BF 47.60 52.99 48.45 63.34 16.68 54.20 -8.40 55.97 29.80 
 
 MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 BV 77.90 66.45 -14.70 64.05 -3.61 143.30a 123.73 75.20a -47.52 
JC36 PS 25.28 30.25 19.68 43.05a 42.31 53.25a 23.69 51.65 -3.00 
JC36 BF 55.98 45.80a -18.18 54.90 19.87 107.30a 95.45 72.95a -32.01 
 
 MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
HC38 BV 74.22 70.30 -5.28 82.93 17.97 43.93 -47.03 100.10a 127.85 
HC38 PS 46.78 42.00 -10.22 52.50a 25.00 44.40a -15.43 48.43 9.08 
HC38 BF 68.93 64.97 -5.75 93.73 44.28 40.20a -57.11 74.37a 84.99 
 
 MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
GK39 BV 35.95 35.40 -1.53 30.50 -13.84 25.90 -15.08 24.40 -5.79 
GK39 PS 36.35 21.80a -40.03 20.40 -6.42 15.40 -24.51 17.50 13.64 
GK39 BF 17.90 48.2a 169.27 41.4 -14.11 15.10a -63.53 20.60 36.42 
 
aIndividual change in BV/ PS/ BF >2x mean difference between 2 baseline scans  
bGroup change in BV/ PS/ BF >2x mean difference between 2 baseline scans 
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; 5# RT- 1 hour after fifth fraction of radiotherapy; CA4P1 – 4 hours 
after the first dose of CA4P; 72h 1- 72 hours after the first dose of CA4P 
 
Table 7.1  
DCE-CT derived median blood volume (BV) values (ml/100ml), median permeability 
surface area product (PS) values (ml/100ml/min) and median Blood Flow (BF) 
values (ml/100ml/min), together with percentage change from previous time point, 
for each patient and group mean (UKR104 cohort 6). 
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Graph of median single level tumour blood volume for HNSCC patients receiving 
weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the following time 
points: MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; 
CA4P1 – 4 hours after the first dose of CA4P; 72h 4 – 72 hours after the first dose of 
CA4P; 25# RT- 1 hour after twenty fifth fraction of radiotherapy; CA4P4 – 4 hours 
after the fourth dose of CA4P; 72h 4 – 72 hours after the fourth dose of CA4P. 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 77.90 66.45 -14.70 64.05 -17.78 143.30a 83.95 75.20 -3.47 
HC38 74.22 70.30 -5.28 82.93 11.74 43.93 -40.80 100.10 34.88 
GK39 35.95 35.40 -1.53 30.50 -15.16 25.90 -27.96 24.40 -32.13 
Mean 62.69 57.38 -7.17 59.16 -7.06 71.04 5.06 66.57 -0.24 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  144.90a 95.24 107.65 45.05 111.85 50.71   
 
aIndividual change in BV >2x mean difference between 2 baseline scans  
bGroup change in BV >2x mean difference between 2 baseline scans  
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; 5# RT- 1 hour after fifth fraction of radiotherapy; CA4P1 – 4 hours 
after the first dose of CA4P; 72h 1- 72 hours after the first dose of CA4P; 25# RT- 1 hour 
after twenty fifth fraction of radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 
72h 4- 72 hours after the fourth dose of CA4P; 6# RT- 1 hour after sixth fraction of 
radiotherapy; CA4P4 – 4 hours after the third dose of CA4P. 
 
Table 7.2  
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from mean baseline for patients with SCC Head & Neck receiving weekly 
CA4P, cetuximab and RT (UKR104 cohort 6). 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 77.90 66.45 -14.70 64.05 -3.61 143.30a 123.73 75.20a -47.52 
HC38 74.22 70.30 -5.28 82.93 17.97 43.93 -47.03 100.10a 127.85 
GK39 35.95 35.40 -1.53 30.50 -13.84 25.90 -15.08 24.40 -5.79 
Mean 62.69 57.38 -7.17 59.16 0.17 71.04 20.54 66.57 24.84 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  144.90a 44.76 107.65 -25.71 111.85 3.90   
 
aIndividual change in BV >2x mean difference between 2 baseline scans  
bGroup change in BV >2x mean difference between 2 baseline scans  
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; 5# RT- 1 hour after fifth fraction of radiotherapy; CA4P1 – 4 hours 
after the first dose of CA4P; 72h 1- 72 hours after the first dose of CA4P; 25# RT- 1 hour 
after twenty fifth fraction of radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 
72h 4- 72 hours after the fourth dose of CA4P; 6# RT- 1 hour after sixth fraction of 
radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 7.3  
DCE-CT derived median blood volume (BV) values (ml/100ml) and percentage 
change from previous time point for patients with SCC Head & Neck receiving 
weekly CA4P, cetuximab and RT (UKR104 cohort 6). 
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Graph of median single level tumour permeability surface area product for HNSCC 
patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the 
following time points: MB- mean baseline; 2# RT- 1 hour after second fraction of 
radiotherapy; CA4P1 – 4 hours after the first dose of CA4P; 72h 4 – 72 hours after 
the first dose of CA4P; 25# RT- 1 hour after twenty fifth fraction of radiotherapy; 
CA4P4 – 4 hours after the fourth dose of CA4P; 72h 4 – 72 hours after the fourth 
dose of CA4P. 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 25.28 30.25 19.68 43.05a 70.33 53.25a 110.68a 51.65a 104.35 
HC38 46.78 42.00 -10.22 52.50a 12.22 44.40 -5.09 48.43 3.53 
GK39 36.35 21.80a -40.03 20.40a -43.88 15.40a -57.63a 17.50a -51.86 
Mean 36.14 31.35 -10.19 38.65 12.89 37.68 15.98 39.19 18.67 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  58.60a 25.26 72.65a 55.29 82.15a 75.60   
 
aIndividual change in PS >2x mean difference between 2 baseline scans  
bGroup change in PS >2x mean difference between 2 baseline scans 
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; CA4P1 – 4 hours after the first dose of CA4P; 72h 1- 72 hours after 
the first dose of CA4P; 25# RT- 1 hour after twenty fifth fraction of radiotherapy; CA4P4 – 4 
hours after the fourth dose of CA4P; 72h 4- 72 hours after the fourth dose of CA4P; 6# RT- 1 
hour after sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 7.4  
DCE-CT derived median permeability surface area product (PS) values 
(ml/100ml/min) and percentage change from mean baseline for patients with SCC 
Head & Neck receiving weekly CA4P, cetuximab and RT (UKR104 cohort 6). 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 25.28 30.25 19.68 43.05a 42.31 53.25a 23.69 51.65 -3.00 
HC38 46.78 42.00 -10.22 52.50a 25.00 44.40a -15.43 48.43 9.08 
GK39 36.35 21.80a -40.03 20.40 -6.42 15.40 -24.51 17.50 13.64 
Mean 36.14 31.35 -10.19 38.65b 20.30 37.68 -5.41 39.19 6.57 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  58.60a 20.99 72.65a 23.98 82.15a 13.08   
 
aIndividual change in PS >2x mean difference between 2 baseline scans  
bGroup change in PS >2x mean difference between 2 baseline scans 
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; CA4P1 – 4 hours after the first dose of CA4P; 72h 1- 72 hours after 
the first dose of CA4P; 25# RT- 1 hour after twenty fifth fraction of radiotherapy; CA4P4 – 4 
hours after the fourth dose of CA4P; 72h 4- 72 hours after the fourth dose of CA4P; 6# RT- 1 
hour after sixth fraction of radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 7.5 
DCE-CT derived median permeability surface area product (PS) values 
(ml/100ml/min) and percentage change from previous time point for patients with 
SCC Head & Neck receiving weekly CA4P, cetuximab and RT (UKR104 cohort 6). 
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Graph of median single level tumour blood flow for HNSCC patients receiving 
weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the following time 
points: MB- mean baseline; 2# RT- 1 hour after second fraction of radiotherapy; 
CA4P1 – 4 hours after the first dose of CA4P; 72h 4 – 72 hours after the first dose of 
CA4P; 25# RT- 1 hour after twenty fifth fraction of radiotherapy; CA4P4 – 4 hours 
after the fourth dose of CA4P; 72h 4 – 72 hours after the fourth dose of CA4P. 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 55.98 45.80a -18.18 54.90 -1.92 107.30a 91.69 72.95a 30.33 
HC38 68.93 64.97 -5.75 93.73a 35.98 40.20a -41.68 74.37 7.88 
GK39 17.90 48.2a 169.27 41.4a 131.28 15.1 -15.64 20.6 15.08 
Mean 47.60 52.99 48.45 63.34b 55.11 54.20 11.46 55.97 17.76 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  98.80a 43.33 129.05a 87.21 72.70 5.46   
 
aIndividual change in BF >2x mean difference between 2 baseline scans  
bGroup change in BF >2x mean difference between 2 baseline scans 
MB- mean baseline; Cet- 4 to 6 days after first dose of cetuximab and prior to the first 
fraction of radiotherapy; 5# RT- 1 hour after fifth fraction of radiotherapy; CA4P1 – 4 hours 
after the first dose of CA4P; 72h 1- 72 hours after the first dose of CA4P; 25# RT- 1 hour 
after twenty fifth fraction of radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 
72h 4- 72 hours after the fourth dose of CA4P; 6# RT- 1 hour after sixth fraction of 
radiotherapy; CA4P3 – 4 hours after the third dose of CA4P. 
 
Table 7.6  
DCE-CT derived median Blood Flow (BF) values (ml/100ml/min) and percentage 
change from mean baseline for patients with SCC Head & Neck receiving weekly 
CA4P, cetuximab and RT (UKR104 cohort 6). 
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  MB Cet change (%) 5#RT change (%) CA4P1 change (%) 72h 1 change (%)
JC36 55.98 45.80a -18.18 54.90 19.87 107.30a 95.45 72.95a -32.01 
HC38 68.93 64.97 -5.75 93.73 44.28 40.20a -57.11 74.37a 84.99 
GK39 17.90 48.2a 169.27 41.4 -14.11 15.10a -63.53 20.60 36.42 
Mean 47.60 52.99 48.45 63.34 16.68 54.20 -8.40 55.97 29.80 
          
  25#RT change (%) CA4P4 change (%) 72h 4 change (%)   
HC38  98.80a 32.86 129.05a 30.62 72.70a -43.67   
 
aIndividual change in BF >2x mean difference between 2 baseline scans  
bGroup change in BF >2x mean difference between 2 baseline scans 
MB- mean baseline Cet- 4 to 6 days after first dose of cetuximab and prior to the first fraction 
of radiotherapy; 5# RT- 1 hour after fifth fraction of radiotherapy; CA4P1 – 4 hours after the 
first dose of CA4P; 72h 1- 72 hours after the first dose of CA4P; 25# RT- 1 hour after twenty 
fifth fraction of radiotherapy; CA4P4 – 4 hours after the fourth dose of CA4P; 72h 4- 72 hours 
after the fourth dose of CA4P; 6# RT- 1 hour after sixth fraction of radiotherapy; CA4P3 – 4 
hours after the third dose of CA4P. 
 
Table 7.7 
DCE-CT derived median Blood Flow (BF) values (ml/100ml/min) and percentage 
change from previous time point for patients with SCC Head & Neck receiving 
weekly CA4P, cetuximab and RT (UKR104 cohort 6). 
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Graph of individual and group mean changes in white cell count for HNSCC patients 
receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the 
following time points: PreCA4P- after third or fourth fraction of radiotherapy in week 
of sampling, after second dose of cetuximab and prior to CA4P; 4h- 4 hours after 




































Graph of individual and group mean changes in neutrophil count for HNSCC 
patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the 
following time points: PreCA4P- after third or fourth fraction of radiotherapy in week 
of sampling, after second dose of cetuximab and prior to CA4P; 4h- 4 hours after 









































Graph of individual and group mean changes in lymphocyte count for HNSCC 
patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the 
following time points: PreCA4P- after third or fourth fraction of radiotherapy in week 
of sampling, after second dose of cetuximab and prior to CA4P; 4h- 4 hours after 






































Graph of individual and group mean changes in monocyte count for HNSCC 
patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), plotted at the 
following time points: PreCA4P- after third or fourth fraction of radiotherapy in week 
of sampling, after second dose of cetuximab and prior to CA4P; 4h- 4 hours after 
CA4P; 6- 8h- 6 to 8 hours after CA4P; 1 week- 7 days after CA4P. 
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JC36 PreCA4P 4h  6-8h 1 week 
Hb 135 137 140 124 
Plt 502 490 473 387 
WBC 7.2 13.8 9.9 6.8 
Neu 5.8 12.9 8.5 5.3 
Lym 0.7 0.4 0.7 1.1 
Mon 0.3 0.4 0.6 0.4 
     
HC38 PreCA4P 4h  6-8h 1 week 
Hb 131 125 138 129 
Plt 168 138 145 145 
WBC 3.5 2.3 8 3.1 
Neu 2.1 1.6 7.1 2 
Lym 0.9 0.6 0.6 0.6 
Mon 0.4 0 0.2 0.3 
     
GK39 PreCA4P 4h  6-8h 1 week 
Hb 134 136 131 138 
Plt 254 237 248 323 
WBC 8 7.2 9.9 4.4 
Neu 6.6 6.5 8.9 3.2 
Lym 0.7 0.6 0.4 0.6 
Mon 0.7 0.1 0.5 0.5 
     
JG40 PreCA4P 4h  6-8h 1 week 
Hb 119 127 132 117 
Plt 333 334 346 297 
WBC 6.2 11.7 10.9 6.4 
Neu 3.8 10 9 4.6 
Lym 1.8 1.4 1.4 1.3 




Full blood count results for head and neck cancer patients receiving CA4P, 
cetuximab and radical radiotherapy (UKR104 cohort 6). 
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Graph of individual and group mean changes in plasma VEGF concentration for 
HNSCC patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), 
plotted at the following time points: PreCA4P- after third or fourth fraction of 
radiotherapy in week of sampling, after second dose of cetuximab and prior to 



































Graph of individual and group mean changes in plasma VEGFR1 concentration for 
HNSCC patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), 
plotted at the following time points: PreCA4P- after third or fourth fraction of 
radiotherapy in week of sampling, after second dose of cetuximab and prior to 
































Graph of individual and group mean changes in plasma G-CSF concentration for 
HNSCC patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), 
plotted at the following time points: PreCA4P- after third or fourth fraction of 
radiotherapy in week of sampling, after second dose of cetuximab and prior to 

























Graph of individual and group mean changes in plasma SDF-1 concentration for 
HNSCC patients receiving weekly CA4P, weekly cetuximab and RT (Cohort 6), 
plotted at the following time points: PreCA4P- after 3 to 4 fractions of radiotherapy, 
after second dose of cetuximab and prior to CA4P; 4h- 4 hours after CA4P; 6- 8h- 6 







   
 
A VEGF (pg/ml)   
 Pre CA4P 4h 6-8h 1 week 
JC36  54 107 70 79 
HC38 0 0 0 13 
GK39  42 69 45 0 
JG40 0 96 58 145   
 
 
B VEGF R1 (pg/ml)  
 Pre CA4P 4h 6-8h 1 week 
JC36  131 201 147 60 
HC38 103 176 218 72 
GK39  50 85 128 38 









C G-CSF (pg/ml)   
 Pre CA4P 4h 6-8h 1 week 
JC36  81 77 53 80 
HC38 20 39 91 29 
GK39  83 147 194 50 
JG40 21 54 56 27 
D SDF-1 (pg/ml)   
 Pre CA4P 4h 6-8h 1 week 
JC36  2924 3048 2753 2520 
HC38 3092 2796 2859 3063 
GK39  1845 1994 1953 2067 




ELISA results for head and neck cancer patients receiving CA4P, cetuximab and 
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